Characterization of b-nicotyrine-mediated inactivation of cytochrome P450 2A6 by Kramlinger, Valerie Marie
  
 
 
 
Characterization of beta-nicotyrine-mediated inactivation of cytochrome P450 2A6 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Valerie M. Kramlinger 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
Sharon E. Murphy, Advisor 
 
 
 
 
April 2013 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Valerie M. Kramlinger, 2013 
 
i 
 
Acknowledgements 
 
 
My first and most sincere thanks go to my thesis advisor, Dr. Sharon E. Murphy.  
You have offered me sound advice and careful guidance. Thank you for your time, 
energy and patience.    
 
I would like to express my deep gratitude and respect to Dr. Lisa Peterson, Dr. 
Linda von Weymarn, Dr. Peter Villalta, Brock Matter, Dr. Aaron Titelbaum and Dr. Rory 
Remmel.  Each of you has offered valuable input that contributed to my thesis project. 
 
I would like to thank my fellow graduate students Martin Phillips, Ania Urban, 
Nicole Skinner, Lauren Beech, IlyaTikh, Josh Baller, and Adam Zarth; struggling and 
learning alongside each of you has been an amazing journey.   
 
To my Murphy Lab co-workers, thank you for sharing your expertise and for 
making the lab a friendly environment. 
 
To everyone on the 7th floor of the Cancer Center, thank you for your friendship 
and willingness to share your extensive knowledge on every possible subject. 
 
Finally, to my family, thank you for your unending support and the joy you bring 
to my life.  You constantly inspire me to work hard, persist through difficult moments 
and embrace the world a sense of humor.   
ii 
 
Dedication 
 
 
 
 
 
For my family, who offer me unconditional love and support. 
iii 
 
Abstract 
Nicotine, the primary addictive compound in cigarettes, is metabolized in humans 
by cytochrome P450 2A enzymes. The hepatic enzyme responsible for the metabolism of 
nicotine in smokers is P450 2A6. P450 2A13, which shares 94% primary sequence 
homology with P450 2A6, also catalyzes the metabolism of nicotine and is present in the 
lung.  Loss of P450 2A activity is correlated with modified smoking behavior and 
addiction. Inhibition of these enzymes decreases nicotine metabolism and may be of 
benefit in smoking cessation. 
This thesis investigates tobacco-related molecules that may impact P450 2A 
function and is presented in three parts.  In the first, the potential inhibitory potency of (-
)-menthol, (R)-(+)-menthofuran, and -nicotyrine of both P450s 2A6 and 2A13 are 
investigated. All three compounds inhibit P450 2A6 and 2A13 activity. In addition, 
menthofuran and -nicotyrine mediate mechanism-based inactivation of P450 2A6 but 
not 2A13.  Second, the P450 2A6 and P450 2A13-mediated metabolism of -nicotyrine 
is studied and three metabolites are identified.  -nicotyrine is readily turned over by both 
P450 2A6 and P450 2A13 as indicated by the calculated Km (4.4µM and 5.0µM, 
respectively) and Vmax (21 and 37 pmol product/min/pmol, respectively) values.  Also in 
the second section, -nicotyrine is shown to be a metabolite of P450 2A6-mediated 
nicotine metabolism.  In the last section, attempts to identify a covalent adduct that would 
result from menthofuran or -nicotyrine-mediated inactivation are presented, but these 
are largely unsuccessful.
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Chapter 1  
 
Introduction  
 
 
 
 There has been extensive research on tobacco and its effects on human health.  It 
is well established that tobacco causes cancer and other diseases and major players in 
disease processes have been identified.  It is also known that tobacco use results in 
addiction to nicotine and this addiction propels use which leads to cancer (Figure 1-1). 
This thesis is focused on the study of molecular interaction between less well studied 
tobacco-related molecules and the two enzymes that are implicated in nicotine clearance 
and procarcinogen activation.  Although much of the research presented is mechanistic in 
nature, the big-picture remains focused on how to reduce human disease caused by 
tobacco use, which includes encouraging the discontinuation of tobacco use.  Thus, a 
summary covering general tobacco knowledge is provided below.  
 
 
 
 
 
Figure 1-1. Role of Nicotine Metabolism in Tobacco-Related Cancers. 
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1.1 Tobacco use and health consequences 
Tobacco use is prevalent across the globe and a common method of tobacco use is 
cigarette smoking.  It has been estimated that worldwide there are 1 billion males who 
smoke and 250 million females
1
.  The World Health Organization has indicated that the 
tobacco pandemic is moving from Western countries to developing nations and has 
estimated that about 80% of the people who die from smoking now live in low and 
middle income countries
1;2
.  
Despite this shift, tobacco use persists in the United States.  Approximately 46.6 
million U.S. adults smoke cigarettes
3
.  Although there was a steady decrease in the 
percentage of adult smokers in the US from 1965 (42%) until 2004 (21%), the value has 
plateaued near 20% where it remains to the present day (Figure 1-2).  In 2009, an 
estimated 20% of the teenage population in the United States were self-reported smokers, 
indicating that it is likely there will be no further decline in smoking in the next 
generation 
4
.  In addition to those who smoke, many Americans, including 54% of 
children aged 3–11 years, are exposed to secondhand smoke 5.  
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Figure 1-2. Percentage of American adults who are current cigarette smokers 
6
.   
 
 There are many negative health outcomes that result from tobacco use and 
exposure to secondhand tobacco smoke.  Lung cancer is the most well-known but there is 
sufficient evidence that cancers of the lung, larynx, nasal cavity, oral cavity, esophagus, 
liver, pancreas, bladder, cervix and leukemia are associated with tobacco use
7
.  
Additionally, coronary heart disease, stroke, chronic obstructive lung diseases (such as 
chronic bronchitis and emphysema) and reproductive problems are linked to tobacco 
use
7
.  In U.S. fifty percent of smokers die as a direct consequence of their tobacco 
addiction, this sums to an estimated 400,000, or one in every five deaths, every year 
8;9
.  
Health risks from smoking are not limited to the smoker; it has been estimated that 
worldwide 600,000 people die each year from exposure to secondhand tobacco smoke
1;10
.  
Tobacco is considered a major preventable cause of morbidity and mortality, but it is a 
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challenging problem.  Preventing or successfully treating addiction to tobacco products is 
imperative.   
 
1.2 Tobacco regulation and smoking cessation 
 The United States has a long history of using state and federal legislation in 
attempts to reduce tobacco use and secondhand smoke exposure in the population. Efforts 
are typically targeted toward the regulation of tobacco sales, marketing, and use.  Federal 
legislation include acts that require labeling cigarette packages as hazardous (1965), 
obligate reports of any additives used in manufactured tobacco products (1984) and the 
prohibition of smoking on airplanes (1989) and in clinics that treat women and children 
(1993)
11
.  State legislation has mandated a smoking ban in 22 states, however the 
specifics vary from state to state
12
.  Current approaches to decrease tobacco use include 
smoke-free legislation, taxes on tobacco products to raise prices, bans on product 
promotion, education outreach, warning labels and accessible quit programs.  In 2009, the 
Family Smoking Prevention and Tobacco Control Act granted the Food and Drug 
Administration (FDA) the authority to regulate tobacco products.  Under this act, a ban 
on cigarettes containing certain characterizing flavors went in to effect.  This ban did not 
include menthol, a common cigarette flavoring that provides a sort of coolness in the 
mouth while smoking.  Menthol cigarettes are preferred by 75% of African American 
smokers but only 23% of Caucasian smokers 
13
.  African Americans have higher lung 
cancer incidence rates (74.7 per 100,000) than any other ethnic or racial group, including 
Caucasians (64.4 per 100,000) 
13;14
. The correlation generated controversy since menthol 
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is reported to modify nicotine metabolism and has thus been the focus of recent FDA 
regulation 
15-17
.  
Despite governmental efforts, there are several challenges to decreasing tobacco 
use in the U.S.  The tobacco industry has strong roots in the global economy; Philip 
Morris, the largest US-based cigarette company, has yearly revenues of around 44 billion 
dollars and a high trade surplus, resulting in it being a high US tax-payer 
18
.  As a result, 
tobacco companies have had influence in the negotiations regarding tobacco legislation 
and are actively developing new products and strategies to promote tobacco use that 
circumvent the resulting policies.    
Anti-smoking policies and increased awareness of health risks have resulted in 
decreased tobacco use in the United States though some demographics maintain higher 
rates of smoking.  The percentage of smoking American adults from the population that 
is at or above the poverty level (18%) is substantially lower than from the population that 
is below the poverty level (29%) 
3
. Additionally, those with higher levels of education 
tend to smoke less (Figure 1-3) 
3
.  Those of a lower economic status are less likely to 
have access to healthcare and are thus likely to be affected more by tobacco-related 
health problems. 
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Figure 1-3. Percentage of adult smoking by education level
3
. 
 
From 2000 to 2004, cigarette smoking was estimated to be responsible for $193 
billion in annual health-related economic losses in the United States 
19
.  Tobacco also 
creates economic costs that extend beyond the direct cost of related illness and 
productivity losses, including health care expenditures from active and passive smokers, 
employee absenteeism, reduced labor productivity, fire damage due to careless smokers, 
increased cleaning costs, and widespread environmental damage 
19
.  The health and 
economic consequences of tobacco use are entirely preventable. 
Quitting tobacco simultaneously reduces health risks and produces long-term 
health benefits 
20
.  Despite the potential mitigating effects of quitting, many continue to 
use tobacco.  The Center for Disease Control (CDC) informs us that in 2010, 69% of 
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adult smokers reported that they would like to quit, 52% actually made a quit attempt but 
only 6.2% were successful in their attempt 
21
.  These quitting statistics are explained by 
research that compares the strength of addiction to nicotine, the addictive compound in 
tobacco, to heroin, cocaine, or alcohol 
22
.   
 
1.3 Relevant components of tobacco 
There are over 4,000 chemicals in tobacco smoke.  This mix contains many 
known or suspected human carcinogens and toxic agents.  The FDA has recognized 93 of 
these compounds as harmful and 69 are known carcinogens 
23
.  The way to minimize 
exposure to these harmful compounds is to discontinue tobacco use.  However many 
users struggle to quit because of the strength of nicotine addiction.  Therefore, the study 
of compounds that cause or mitigate damaging effects of tobacco or influence addiction 
are of particular interest.   
 
1.3.1 Nicotine  
 Nicotine is the addictive agent in tobacco products and it is the primary reason 
why people continue their use 
24
.  Found in the leaves of the Solanaceae family of plants, 
which include tomatoes, potatoes and tobacco, nicotine functions as a natural pesticide 
that is toxic to insects.  Most of these plants have very low levels of nicotine (4-100 
ng/g)
25
. In tobacco plant leaves, however, nicotine is up to 3% (30mg/g) of the dry 
weight.  
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The effects of nicotine are related to blood levels of nicotine, the kinetics of 
exposure and the resulting psychoactive effect.  Nicotine is an alkaloid that acts as an 
acetylcholine analogue in humans.  One cigarette contains 10-14 mg of nicotine and a 
smoker inhales an estimated 1mg per cigarette smoked 
26
.  When tobacco smoke reaches 
the lungs, nicotine is rapidly absorbed and reaches the brain in 10-20 seconds.  In the 
brain, nicotine binds to nicotinic cholinergic receptors, causing complex effects that are 
mediated by dopinergic and nondopinergic neurons 
27;28
.  Blood concentrations of 
nicotine rise quickly during smoking and peak at the completion of the cigarette. Peak 
nicotine concentrations provide the smoker with sought effects, typically relaxation, 
reduced stress and pleasant mood 
28
.  The rapid rise in nicotine levels permits the smoker 
to titrate the level of nicotine during smoking 
29;30
.  Though smokers seek out the 
favorable effects that occur at peak nicotine levels, smoking behavior more closely 
corresponds to maintaining a threshold concentration in the blood 
30
.  Maintaining a 
nicotine threshold mitigates withdrawal symptoms, which include nervousness, 
restlessness, irritability and anxiety.  Supporting this idea of nicotine threshold 
maintenance, cigarette smokers switching from a higher to a lower-yield cigarette or 
reducing the number of cigarettes smoked, will compensate, i.e., will change the smoking 
pattern to gain more nicotine 
31-33
.  
The amount of circulating nicotine is a function of the dose consumed and the rate 
of elimination 
26
.  The primary route of nicotine elimination is through hepatic 
metabolism, though some metabolism occurs in other tissues including the lungs and 
kidney 
29
.  Nicotine's conversion to cotinine through 5'-oxidation is the major metabolic 
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pathway.  None of the major metabolites have psychoactive properties.  In most people 
nicotine-C-oxidation to generate cotinine is the major metabolic pathway.  In most 
smokers, about 70–80% of the nicotine dose is excreted as cotinine and its metabolites 
(Figure 1-4) 
34
.  Ninety percent of a systemic dose of nicotine can be accounted for as 
nicotine and metabolites in the urine 
35
. Thirty to 40% is excreted as trans-3'-
hydroxycotinine, a subsequent oxidation product of cotinine.  Unchanged nicotine 
accounts for only 8-10% of the dose 
34
.  The average half-life of nicotine is two hours, 
however the rate of metabolism and distribution of metabolites vary among individuals 
36
.   
 
Figure 1-4. Quantitative scheme of nicotine metabolism.  Based on estimates of average 
excretion of metabolites as percent of total urinary nicotine
26
.   
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1.3.2 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK) 
Among the 69 known tobacco carcinogens is the tobacco specific human lung-
carcinogen, NNK 
37
.  NNK is structurally related to nicotine, and is formed during the 
tobacco curing process (Figure 1-5).  Considerable evidence favors NNK as major 
etiological factors in lung cancer, particularly important in the induction of 
adenocarcinoma 
38
.  
 
 
Figure 1-5: Structure of nicotine and NNK 
 
Levels of NNK are abundant; albeit 10,000-fold lower than nicotine (433-733 ng 
NNK/cigarette) 
37;38
.  Metabolism of NNK is necessary for carcinogenesis, requiring 
hydroxylation alpha to the N-nitroso moity 
39
.  This hydroxylation is efficiently catalyzed 
by an enzyme present in the lung suggesting that tissue specific activation of NNK 
contributes to the heightened risk of lung cancer among smokers. 
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1.3.3 1-methyl-2-(3-pyridyl) pyrrole (β-nicotyrine) 
Although nicotine is the predominant tobacco alkaloid, there are a handful of 
other 'minor' alkaloids present in tobacco.  Included in this list are anatabine, anabasine, 
mysomine, and β-nicotyrine.  The structures of the aforementioned alkaloids are similar 
to nicotine.  β-nicotyrine differs from nicotine only in that the pyrrolidine ring has been 
aromatized by the loss of four hydrogen atoms (Figure 1-6).   
 
 
Figure 1-6: Nicotine and minor tobacco alkaloids. 
 
 β-Nicotyrine is present in tobacco and is a product of thermal decomposition of 
nicotine 
40;41.  It is speculated that β-nicotyrine is generated during the curing process of 
tobacco as well as the burning of a cigarette.  The amount of β-nicotyrine in tobacco 
smoke has been reported to range from 4-40 µg per cigarette compared to 2-20 µg for 
12 
 
anatabine and 0.8 to 2.3 mg for nicotine 
42;43.  β-nicotyrine has also been detected in 
environmental tobacco smoke and in the E-cigarette 
44;45
. 
β-nicotyrine is present in tobacco and tobacco smoke but the physiological 
implications, if any remain unknown.   In animal tissues, β-nicotyrine is reported to 
possess some weak nicotine-like pharmacological activities 
46
.  No work has been done 
looking at the physiological effects of β-nicotyrine in humans.   
Little is known of β-nicotyrine metabolism in smokers.  There is one published 
study in which β-nicotyrine (a 2 mg oral dose) was given to humans 47. No unchanged β-
nicotyrine was detected in urine collected for 24 h following administration.  In the same 
study, 15% of the administered nicotine dose was recovered.  These data suggest β-
nicotyrine is extensively metabolized in humans. 
The metabolism of β-nicotyrine by rabbit liver and lung has been studied.  NADPH-
supplemented rabbit lung and liver microsomal preparations convert β-nicotyrine to four 
metabolites 
48
. The primary metabolites (Figure 1-7) were shown to be an equilibrium 
mixture of two unstable pyrrolinone species, 1-methyl- 5-(3-pyridinyl)-4-pyrrolin-2-one 
(4) and 1-methyl-5-(3-pyridinyl)-3-pyrrolin-2-one (5). These isomeric pyrrolinones 
undergo autoxidation, to form 5-hydroxy-1-methyl-5-(3-pyridinyl)-3-pyrrolin-2-one (6), 
and hydration, to form 5'-hydroxycotinine (7)
49
.  
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Figure 1-7. Proposed pathway for β-nicotyrine metabolism. 
 
This thesis focuses on the interactions between tobacco-related molecules, such as β–
nicotyrine or menthol, and the enzymes that are responsible for nicotine and NNK 
metabolism.  Considering the large number of smokers and the highly addictive 
properties of tobacco, a better understanding of the molecular components of tobacco that 
may contribute to the development and maintenance of a tobacco addiction is warranted.   
 
(1) (2) (3) 
(4) 
(5) 
(6) 
(7) 
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Figure 1-8. Fe(III) protoporphyrin-IX heme. 
 
1.4 Cytochrome P450 Enzymes (P450s) 
Nicotine and NNK are 
metabolized by enzymes that are 
members of the P450 superfamily.  
Cytochrome P450 enzymes comprise a 
large superfamily of monooxygenases 
that are present in animals, plants, fungi 
and bacteria.  These enzymes were first 
discovered in 1958 as carbon-monoxide 
binding pigment in pig and rat liver 
microsomes 
50;51
 Later, the enzyme was characterized as a hemoprotein and called 
“P450” because of the Soret peak at 450 nm in their reduced form when saturated 
with carbon monoxide
52;53
.  P450s contain an Fe(III) protoporphyrin-IX heme in their 
active site 
54
.  The absorption maximum at 450 nm depends on a properly incorporated 
heme.  Nitrogen atoms of the porphyrin provide the first four ligands and a cysteine 
thiolate acts as the fifth ligand of the heme iron (Figure 1-8).   
Carbon monoxide difference spectra are routinely used to quantify the amount of 
P450 enzyme that contains a properly incorporated heme.  Substrate or inhibitor binding 
to P450s can be analyzed by following changes in the UV-visible heme Soret spectrum 
that result from displacement of the water or an amino acid ligand from the heme iron 
(type I spectrum), or from direct coordination of ligand to the heme iron (type II 
spectrum) 
55
. 
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P450s are capable of acting on a diverse range of endogenous and exogenous 
substrates.  Reactions catalyzed by P450s include hydrocarbon hydroxylation, heteroatom 
oxidation and dealkylation (heteroatom release), aromatic ring oxidation, acetylene 
oxidation, dehydrogenation carbon-carbon bond cleavage and radical cross-linking of 
substrates 
56;57
.  Although there are several exceptions, the general reaction catalyzed by 
P450s is one of mixed-function oxidation (as shown below where S is the substrate and 
SO is the oxidized product).  These reactions require molecular oxygen and reducing 
equivalents supplied by NADPH or NADH as well as a protein partner, P450 
oxidoreductase, for electron transfer. 
 
 
 
Most of the P450 catalytic cycle is widly accepted.   The cycle starts with the 
heme iron in the ferric (Fe
III
) state (I).  The substrate binds the low spin ferric heme iron, 
forming a high spin ferric iron (II).  Upon the addition of the first electron, which is 
supplied by NAD(P)H via redox protein partners, the iron is then reduced to a ferrous 
(Fe
II
) state (III).  Ferrous heme iron then binds molecular oxygen (O2) producing Fe
II
-O2 
(not shown).  This complex then undergoes a conversion to a more stable complex anion 
complex (IV). Next, a second electron transfer, sometimes delivered from cytochrome 
b5, occurs.  A comparison between the bond energies of O2, O2
-
 and O2
2-
 suggest that the 
Fe
III
 O2
2- 
complex is then formed (V).  Then, the first protonation occurs on the distal 
oxygen to generate an Fe
III
 hydroperoxo (VI).  A second distal protonation leads to 
S + O2 + 2 e
-
 + 2 H
+
                  SO + H2O 
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heterocyclic O-O bond scission, generating water and a porphyrin π cation radical iron V 
(VII).  Finally, the iron V species transfers its active oxygen atom to the substrate, 
forming monooxygenated product and regenerated ferric P450. 
 
 
 
Figure 1-9.  Cytochrome P450 catalytic cycle. 
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1.4.1 Human Cytochrome P450s 
Human P450s contribute to normal development and homeostasis by 
metabolizing lipids, steroids, vitamins, eicosanoids, retinoids and prostaglandins.  They 
also metabolize xenobiotics.  There are 57 P450 genes as well as 58 pseudogenes that 
have evolved from several gene duplication and deletion events.  Human P450s are 
membrane-bound and are primarily localized in the endoplasmic reticulum of the cells.  
Six P450s are found exclusively in the mitochondria; these are primarily involved in 
steroid metabolism 
58
.   
There is wide variation in P450 activity.  Regulatory networks including nuclear 
receptors and transcription factors define the tissue-specific distribution of individual 
P450s and modulate constitutive and inducible expression 
59
.  Many factors, both 
physiological and environmental, contribute to individual variability in P450 induction; 
included in this list are disease, gender, age, endocrine homeostasis, dietary components, 
and environmental ligands
60
.  Xenobiotic-metabolizing P450s are highly polymorphic 
and this leads to variation in the levels of enzymes and catalytic function.  Furthermore, 
P450 activity is affected by exposure to inhibitors.  Over 90% of drugs on the market are 
metabolized by a relatively small number of P450s, 3A4/3A5>2D6>2C9>2E1≈1A2, 
listed here in order of their relative contribution to drug metabolism 
61
.  The role of these 
enzymes is extensively studied to predict the potential for adverse drug reactions and 
variation in drug efficacy.   
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1.4.2 Human P450 2A Subfamily 
Two human P450 enzymes, P450 2A6 and P450 2A13, play key roles in the 
metabolism of nicotine and NNK and are thus of particular interest to those studying 
tobacco addiction and carcinogenesis and are the focus of this thesis 
39;62-64
.  P450 2A6 is 
primarily a hepatic enzyme and P450 2A13 is expressed in the respiratory tract 
65;66
. 
Cytochrome P450 2A13 mRNA is highest in the respiratory tract, but only ~5- and ~9-
fold higher than CYP2A6 mRNA in nasal mucosa and lung, respectively 
65;67
.  In 
contrast, in the liver CYP2A6 mRNA is ~1,900-fold higher than CYP2A13.  In the liver, 
P450 2A6 is reported to make up 1-10% of the total P450 
68
.  In human liver, xenobiotic 
metabolism by and inhibition of P450 2A13 is likely to be negligible, but in the 
respiratory tract, both P450 2A6 and P450 2A13 enzymes may contribute depending on 
the substrate or inhibitor.   
P450 2A6 and P450 2A13 primary sequences are 94% sequence identical.  
Accordingly, overall the P450 2A13 and P450 2A6 structures are very similar (α-C of 
RMSD 0.5 A˚) 69. The active site cavity for both enzymes is small and highly 
hydrophobic with a cluster of phenylalanine residues composing the active site roof.  
Amino acid differences between the two enzymes at positions 117, 300, 301, and 208 
result in changed ligand orientations as well as a smaller active site volume in P450 2A6 
(281.7 A˚3) than P450 2A13 (309.4 A˚3) 70.  These P450s have substantial overlapping 
substrate selectivity; substrates for these enzymes tend to be small molecules with planar 
rings, however there are exceptions, such as in the case of P450 2A13 metabolism of 
testosterone 
71;72
.   
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Despite the similarities, in some cases these two P450 2As exhibit different 
catalytic efficiencies and generate unique products 
65;72-74
.  One common substrate, 
coumarin, is frequently used to probe P450 2A activity.  P450 2A6 selectively catalyzes 
the 7-hydroxylation of coumarin but, P450 2A13 catalyzes both the 7-hydroxylation and 
3,4 epoxidation of coumarin 
75
.  Another marked difference in these enzymes is the 
superior ability of P450 2A13 to activate the tobacco-specific procarcinogen NNK 
through α-hydroxylation 65;72-74.  This hydroxylation results in a diazonium ion that can 
generate DNA adducts and initiate lung cancer 
76
.  P450 2A13 is a 200-fold more 
efficient catalyst of NNK hydroxylation (kcat/Km) than is P450 2A6 
39
.  The high 
efficiency with which P450 2A13 activates NNK combined with its presence in 
respiratory tissues suggests that it plays a critical role in tobacco-induced lung cancer.  
P450 2A13 is also a somewhat superior catalyst of nicotine metabolism; catalyzing 
nicotine 5'-oxidation at a 5- to 20-fold higher catalytic efficiency than P450 2A6 
63;77
.   
 
1.4.3 Nicotine metabolism by P450 2As 
Quantitatively, the most important metabolite of nicotine is the lactam derivative 
cotinine.  In humans, typically 80% of nicotine is converted to cotinine 
76
.  Both P450 
2A6 and P450 2A13 catalyze the 5'-oxidation of nicotine with higher catalytic efficiency 
than other P450s.  The product of this 5'-oxidation generates the immediate product, 5'-
hydroxynicotine, which is in equilibrium with the nicotine
Δ1',5'
iminium ion (Figure 1-10).  
A second P450-catalyzed oxidation is then carried out converting the iminium ion to 
cotinine.  In vivo, a second enzyme, aldehyde oxidase may convert the iminium ion to 
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cotinine.  In humans, due to its presence in the liver, P450 2A6 is the main catalyst of 
nicotine 5'-oxidation 
26
.  Individuals with no P450 2A6 due to a genetic deletion have a 
greater than 85% reduction in 5'-oxidation 
78-80
. 
 
 
Figure 1-10. Major pathways of nicotine metabolism in humans. 
 
Both in vitro and in vivo studies have demonstrated considerable interindividual 
variation in P450 2A6 activity. 
81-84
 Genetic variation in the P450 2A6 gene locus has 
been shown to contribute to this variability.  To date, 38 numbered and 2 duplication 
alleles have been identified
85
;  nineteen of these have been shown to have reduced 
activity in vitro and or in vivo. In some studies, individuals who are heterozygous for 
defective alleles smoked fewer cigarettes per week than smokers homozygous for wild-
type and were less likely to become nicotine dependent 
86;87
.  This genetic variation 
affecting P450 2A6 activity is not generally associated with adverse effects on drug 
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clearance, suggesting that P450 2A6 inhibition is unlikely to alter the metabolism of other 
drugs 
58
. 
Pharmacologically blocking P450 2A6 enzymatic activity decreases the rate of 
nicotine elimination and subsequently can reduce the extent of smoking 
88;89
.  Therefore, 
the identification and characterization of specific and potent inhibitors of P450 2A6 will 
contribute to the design of drugs to modify tobacco consumption. 
Mechanism based inactivation, or suicide inhibition, of P450 2A6 and P450 2A13 
has been reported in a number of studies, but is fully characterized in very few.  
Mechanism-based inactivators are specific and potent inhibitors and harnessing the 
relevant chemistry would lead to powerful drug design.  Inactivation of both P450 2A6 
and P450 2A13 occurs during nicotine metabolism 
77
.  However, nicotine is not the agent 
of inactivation; a secondary or even tertiary nicotine metabolite is likely the inactivator.  
The species responsible for enzyme inactivation has yet to be identified, however one 
possible contender is -nicotyrine.  It has been suggested that -nicotyrine is a 
mechanism-based inactivator of P450 2A6, however, the data supporting this is 
minimal
90
.   
 
1.4.4 β-nicotyrine as a potential metabolite of nicotine 
Nicotine metabolism has been extensively characterized in humans and 90% of a 
systemic dose of nicotine can be accounted for as nicotine and metabolites in the urine 
35;91
. It is possible that β-nicotyrine could be among metabolites that make up the 
remaining ten percent.  To date, two literature references suggest β-nicotyrine could be a 
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metabolite of nicotine 
92-94
.  In dogs and rats, he first identified that -nicotyrine is a 
urinary metabolite of (S)-nicotine. The second was an in vitro experiment with liver 
homogenate from rabbit and guinea pig in which β-nicotyrine was detected as an oxygen 
and NADPH-dependent metabolite of nicotine.  This shows that, in rodents and dogs, β-
nicotyrine is a product of nicotine metabolism.  -Nicotyrine has not been identified as a 
nicotine metabolite in humans.  Regardless, smokers are exposed to -nicotyrine since it 
is in tobacco and therefore an understanding of the impact of this compound on nicotine 
metabolism is warranted. 
 
1.5 Goals of this research 
The importance of understanding the effects of tobacco constituents on P450 2A6 
and P450 2A13 activity is underscored by their potential impact on smoking behavior and 
NNK activation.  In addition, the characterization of potential mechanism-based 
inactivators may aid in the design of potent and specific inactivators of these enzymes.  
That could lead to drug development to aid in smoking cessation. 
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Chapter 2 
 
Substrate binding and inhibition of Cytochrome 
P450 2A6 and Cytochrome P450 2A13 
 
2.1 Introduction 
Tobacco use results in exposure to a number of harmful compounds and 
subsequently can lead to a multitude of negative health outcomes, including cancer.    
Included in the list of harmful compounds is the tobacco specific carcinogen NNK, which 
forms during the curing of tobacco.  Initiation of carcinogenesis by NNK occurs as a 
result of metabolic activation by P450-catalyzed α–hydroxylation to a reactive species 
that alkylates DNA 
39
. 
Discontinued use of tobacco products lowers the risk of developing lung and other 
types of cancer.  Despite the potential health consequences, many smokers are unable to 
quit tobacco use due to the presence of the highly addictive compound, nicotine.  
Nicotine is not a carcinogen and toxicity due to nicotine exposure from cigarettes is rare; 
however nicotine metabolism is of interest with regard to understanding nicotine 
addiction and smoking cessation.  Decreased rate of nicotine metabolism may modify 
smoking behavior 
95
 and pharmacologically blocking nicotine metabolism has been 
reported to reduce the extent of smoking 
88
.   
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The human P450 enzymes responsible for the metabolism of nicotine and the 
activation of NNK are P450 2A6 and P450 2A13.  Although both enzymes catalyze 
nicotine metabolism, P450 2A6-mediated oxidation of nicotine is the primary route of 
elimination due to its high concentrations of in the liver 
26
.  Pathways key to NNK 
activation are P450 2A13 catalyzed hydroxylations 
39
.  Both P450 2A6 and P450 2A13 
catalyze these reactions, however structural differences between the two enzymes render 
P450 2A13 the superior catalyst of this reaction 
69;96
. 
Although P450 2A6 and P450 2A13 enzymes share 94% sequence identity and 
nearly identical secondary structure, there is marked structural variation in the active sites 
of these two enzymes.  Five of the 32 amino acid differences between P450 2A6 and 
P450 2A13 are located in the active sites.  These differences lead to a 15-20% increase in 
the volume of the P450 2A13 active site compared to P450 2A6 (250 Å
3
 and 307 Å
3
, 
respectively).  In addition, the active site geometry of P450 2A6 and P450 2A13 are 
dissimilar.  The geometry directs ligand binding to the most favorable orientation.  This 
sometimes results in a ligand having a different orientation in the P450 2A6 active site 
than it does in P450 2A13 
69;70
.  Modeling studies have predicted that NNK binding in the 
P450 2A13 active site sits in a favorable orientation for the generation of a carcinogenic 
metabolite, whereas in P450 2A6 it does not.   
Due to their roles in the metabolism of nicotine and NNK, inhibition of P450 2A6 
and P450 2A13 may modify tobacco consumption and mitigate carcinogenesis.  
Therefore, compounds found in tobacco that potentially inhibit these enzymes are of 
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interest.  In this study, two of these compounds, menthol and β-nicotyrine are 
investigated. 
Menthol is a tobacco additive that has become the focus of recent FDA regulation.  
Epidemiological studies have reported smokers of mentholated versus non-mentholated 
cigarettes have an increased risk of cancer 
97-99
.  More recently, however, a large and 
well-designed study found that lung cancer incidence and mortality actually decreased 
among older adult smokers of mentholated cigarettes compared to smokers of non-
mentholated cigarettes 
100
.  Regardless, a report that menthol inhibits nicotine metabolism 
has prompted further study on the mechanistic basis of this outcome 
15
. 
 
 
Figure 2-1. Structure of menthol, menthofuran, nicotine and β-nicotyrine. 
 
β-nicotyrine is the pyrrolic analogue of nicotine (Figure 2-1).   It is reported to be 
present in tobacco at low levels (4-40 µg/cigarette)
42
.  In rats, administration of β-
nicotyrine decreased the rate of nicotine metabolism and in vitro it inhibits P450 2A6 
90;101.  Additionally, it was suggested that β-nicotyrine is a mechanism-based inactivator 
(MBI) of P450 2A6 
90
.  Based on the little that is known regarding the level of human 
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exposure to β-nicotyrine, its effect, if any, on nicotine and NNK metabolism remain 
unclear. 
The use of MBIs, also known as suicide inhibitors, are attractive candidates in the 
design of new drugs 
102;103
.   The broad definition of an MBI includes any compound that 
is catalytically converted to a form that irreversibly inactivates the enzyme carrying out 
the enzymatic conversion 
104
.  MBIs can be used in the design of drugs that, because of 
their catalytic requirement, selectively inhibit the target enzyme. Additionally, since 
inactivation is irreversible, the potency of a drug that acts as an MBI will be dependent 
on the rate of synthesis of that particular enzyme. 
Mechanism-based inactivation of P450 2A6 and P450 2A13 has been reported for 
several compounds, however it is well characterized for only a few; among these are 
menthofuran and 8-methoxypsoralen (8-MOP).  Menthofuran has been identified as a 
potent MBI of P450 2A6.  Menthofuran-mediated loss of P450 2A6 activity was 
dependent on catalytic turnover and immunohistochemistry analysis provided evidence 
that the apo-protein was modified 
105
.  8-MOP, a MBI of human P450 2A6, has been 
shown to inhibit the conversion of nicotine to cotinine both in vitro and in vivo 
106;107
.  
Inactivation of both P450 2A6 and P450 2A13 occurs during nicotine metabolism 
77
. 
Nicotine, however, is not the agent of inactivation; a secondary or even tertiary nicotine 
metabolite is likely the inactivator. The species responsible for enzyme inactivation has 
yet to be identified; one possible contender is β-nicotyrine.  β-Nicotyrine is a urinary 
metabolite of nicotine in dogs and rats
108
.  Therefore, in addition to direct exposure of 
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smokers to β-nicotyrine in tobacco, exposure to this potential MBI may occur through 
nicotine metabolism.   It has not yet been identified as a nicotine metabolite in humans  
The importance of understanding the effects of tobacco constituents on P450 2A6 
and P450 2A13 activity is underscored by their potential impact on smoking behavior and 
NNK activation. In addition, the characterization of potential mechanism-based 
inactivators may aid in the design of specific inactivators of these enzymes. The 
objectives of the current study were to determine the relative inhibition of P450 2A6 and 
P450 2A13 activity by β-nicotyrine, menthol and menthofuran and to assess inactivation 
of P450 2A6 and P450 2A13 by each of these compounds. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
Menthofuran, menthol, 7-hydroxycoumarin, coumarin, dilauroyl- L-α-
phosphatidylcholine (DLPC), NADPH, bovine serum albumin, catalase, and all other 
biochemical reagents were obtained from Sigma–Aldrich (St. Louis, MO) and were of 
analytical grade. β-Nicotyrine (99% pure) was obtained from Toronto Research 
Chemicals. Trifluoroacetic acid (TFA) was obtained from Pierce Chemical (Rockford, 
IL).  
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2.2.2 Protein Expression and Purification 
The enzymes used in this study were heterologously expressed in Escherichia coli 
and purified according to previously published methods 
71;109;110
.  His-tagged P450 2A13 
and P450 2A6 are full-length enzymes. At saturating concentrations of coumarin (40 or 
100 µM) the rates of coumarin 7-hydroxylation for both P450 2A13 and P450 2A6 were 
comparable with those reported previously 
111
. 
 
2.2.3 Reconstitution of Enzymes 
P450 2A6 and P450 2A13 were reconstituted with rat NADPH-P450 
oxidoreductase (reductase) in a 1:2 ratio with lipid (DLPC, 0.2 µg/pmol P450) and 
incubated for 45 min at 4 °C. Then, 50 mM Tris buffer, pH 7.4 and catalase were added 
to give final concentrations of 1 pmol/µl P450 2A, 2 pmol/µl reductase, 0.2 µg/µl lipid, 
and 60 U/µl catalase. 
 
2.2.4 Spectral binding assays 
Binding titrations with the ligands were conducted at 20°C using a DW2 UV/vis 
spectrophotometer (OLIS, Bogart, GA).  P450 was diluted to 1 µM in 100 mM potassium 
phosphate buffer, pH 7.4. Diluted enzyme was divided equally between two 1.0-ml 
quartz cuvettes (1-cm path length), and a baseline was recorded (300–500 nm). Freshly 
prepared aliquots of ligand dissolved in 10% ethanol were added to the sample cuvette. 
Concentrations ranged from 1nM to 400µM.  An equal volume of 10% ethanol was 
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added to the reference cuvette. Difference spectra were collected (300–500 nm) after 
being allowed to equilibrate at RT for 5 minutes.  During the spectral titrations, the total 
amount of ethanol added did not exceed 2%. Binding to P450 was monitored as the 
absorbance difference (ΔA) between the minimum (420 nm) and the maximum (385 nm). 
The apparent binding constant (KD) and the maximum spectral change (Amax) were 
determined from nonlinear least-squares regression using Sigma Plot kinetics program 
FromSystat Software Inc. (Chicago, IL). 
 
2.2.5 P450 coumarin 7-hydroxylation activity 
The reaction mixtures contained reconstituted enzyme (5 pmol P450), coumarin 
(0.4–20 µM), NADPH-generating system (0.4 mM NADP, 10 mM glucose 6-phosphate, 
and 0.4 units/ml glucose phosphate dehydrogenase) and 12µg bovine serum albumin in 
300 µl 50 mM Tris buffer, pH 7.4. The reaction was allowed to proceed for 10 min at 
37°C prior to termination by the addition of 30 µl of 15% trichloroacetic acid. To 
investigate inhibition, P450 2A6 or P450 2A13 activity was measured in the presence of 
menthofuran, menthol or β-nicotyrine. Experiments were carried out within the linear 
range of product formation. P450 2A6 reactions contained 0, 1, 2 and 3 µM menthofuran, 
0, 1, 3 and 5 µM β-nicotyrine, or 0, 50, 100 and 200 µM menthol. P450 2A13 reactions 
contained 0, 5, 10 and 25 µM menthofuran, 0, 1, 5 and 10 µM β-nicotyrine, or 0, 50 100 
and 200 µM menthol. 7-Hydroxycoumarin was quantified by HPLC with fluorescence 
detection 
111
. Km, Vmax and KI values were determined using the Sigma Plot kinetics 
program from Systat Software Inc. (Chicago, IL). Ki estimates were determined using 
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nonlinear regression analysis. All data were fit to a competitive inhibition model (Eq. (1)) 
and tested using the Runs test of residuals to determine statistically whether experimental 
data are randomly distributed around the curve with 95% confidence. 
 
V0= Vmax[S] / (Km (1 +[I]/Ki) + [S])         Equation 1 
 
Additionally, global R
2
 values to assess the goodness of fit confirmed that the 
competitive model fit the data sets well (R
2
= 0.92) except for the data set from 
menthofuran inhibition of P450 2A13 (R
2
 = 0.84). All data sets passed the Runs test 
except for the data set from β-nicotyrine inhibition of P450 2A6. 
 
2.2.6 Inactivation 
Inactivation was studied in three types of experiments. Consistent in all three, 
primary reaction mixtures containing menthofuran, menthol or β-nicotyrine and the 
reconstituted enzyme mixture described in Section 2.2.3 were pre-incubated for 5 min at 
30 °C prior to the addition of 1 mM NADPH (or water as a control). At various times 
(including 0 minutes as a control), aliquots (5 µl) were removed and added to 300 µL of a 
secondary reaction mixture (20 µM coumarin, the NADPH-generating system and 40 
µg/ml bovine serum albumin in 50 mM Tris buffer, pH 7.4) and incubated for 10 min at 
30 °C, then 7-hydroxycoumarin formation was quantified as described in Section 2.2.5. 
Inactivation experiments were carried out at 30°C in order to minimize the loss of P450 
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2A6 activity in the presence of NADPH and no inactivator and to be comparable to 
previous literature 
77;111
. 
The first inactivation experiment compared menthofuran, menthol or β-nicotyrine 
as potential inactivators.  Primary reaction mixtures contained uniform inhibitor 
concentration (20 µM) and were allowed to incubate for 10 minutes.  For inhibitor and 
P450 combinations that showed no evidence of inactivation, subsequent experiments 
were performed using increased inhibitor concentrations (200 µM) and time (30 min).  
After the indicated amount of time, aliquots were removed and added to the secondary 
reactions.  
The second type of experiment determined the kinetic parameters for the 
menthofuran and β-nicotyrine-mediated inactivation of P450 2A6.  Either menthofuran 
(0–10 µM) or β-nicotyrine (0–80 µM) were incubated with the primary reaction mixture 
for the indicated times (0–5 min), after which aliquots (5 µl, 5 pmol P450) were removed 
and added to the secondary reaction mixture (as described in the first paragraph of this 
section). Kinetic rate constants were determined from the slopes of the lines when the 
logarithm of the percent activity remaining was plotted against time.  
The third type of inactivation experiment determined the partition ratio for 
menthofuran and β-nicotyrine-mediated inactivation of P450 2A6. The primary reaction 
mixtures containing menthofuran (0–100 µM) or β-nicotyrine (0–100 µM) were 
incubated for 0 or 30 minutes before aliquots were removed and added to the secondary 
reaction mixture. The partition ratio was estimated from the intercept of the regression 
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line obtained at low [inhibitor]/[2A6] ratios and the line obtained at saturating inhibitor 
concentrations 
112
. 
 
2.3. Results 
2.3.1 Ligand binding 
Four compounds (Figure 2-1) were characterized for their binding mode and 
affinity for P450 2A6 and P450 2A13 (Table 2-1). Difference spectra collected upon 
ligand titration of both enzymes with all four compounds resulted in increased 
absorbance at 379-387 nm and decreased absorbance at 414-420 nm (Fig 2-2).  These 
changes are typical of type I interactions, which are typical of substrate binding.  Type I 
binding occurs when a ligand displaces the 6
th
 iron ligand, typically water, resulting in a 
penta-coordinated heme.  None of the compounds displayed type II binding, which is 
typical of an inhibitor.  Type II binding is indicated by an increased absorbance at 431-
432 nm and decreased absorbance at 406-412 nm as a result of replacement of the water 
ligand with the compound, maintaining the hexa-coordinated heme iron. 
The equilibrium dissociation constants were determined for P450 2A6 and P450 
2A13 for each compound. Kd values ranged from 1 to 85μM for P450 2A13 and 5 to 103 
μM for P450 2A6 (Table 2-1). The compounds with the highest affinity for both P450 
2A13 and P450 2A6 were menthofuran (Kd, 1 μM and 5 μM, respectively) and β-
nicotyrine (2 μM and 7 μM, respectively).  Nicotine had an intermediate affinity for P450 
2A13 and P450 2A6, (46 μM and 24 μM, respectively) leaving menthol with the lowest 
affinity for these enzymes (85 μM and 103 μM, respectively). 
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Fig 2-2. UV-visible difference spectra from titration of P450 2A13 with increasing 
concentrations of β-nicotyrine. Not all spectra are shown. Inset is the nonlinear regression 
analysis completed using Sigma Plot from which the KD is obtained. 
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Table 2-1. Calculated dissociation constants for P450 2A binding to menthofuran, -
nicotyrine and menthol and nicotine. 
Ligand
 a
 
KD(µM)
b
 
P450 2A6 P450 2A13 
Menthofuran 5 ± 1.2 1 ± 0.13 
Menthol 103 ± 9.3 85 ± 1.7 
Nicotine 24 ± 2.3 46 ± 0.86 
-nicotyrine 7 ± 2.1 2 ± 0.96 
a Samples were prepared as described in the Materials and methods.   
b KD is obtained by nonlinear regression analysis completed using Sigma Plot.   Values are means ± S.D. 
from three experiments.   
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2.3.2 Inhibition 
The relative inhibition of P450 2A6 and P450 2A13-catalyzed coumarin 7-
hydroxylation by menthol, β-nicotyrine and menthofuran were determined and the kinetic 
constants are presented in Table 2-2. As previously reported, the Km of P450 2A13-
catalyzed coumarin 7-hydroxylation was lower than the Km for P450 2A6 (3.7 and 6.7 
µM, respectively)
75;111. Both menthofuran and β-nicotyrine were relatively potent 
inhibitors of P450 2A6 activity, with KI values of 0.29 µM and 1.07 µM, respectively. 
Inhibition of P450 2A6 by menthol was 100 times less potent (KI of 110 µM). The KI for 
menthol inhibition of P450 2A13, 8.17 µM, was 13 times less than that of P450 2A6. β-
Nicotyrine was also a more potent inhibitor of P450 2A13 than of P450 2A6. The 
inhibition data were analyzed according to several kinetic inhibition models; however, no 
model was determined to be a superior fit to the data as indicated by the goodness of fit 
(R
2
) values. The reported KI values were determined using the competitive inhibition 
model and should be considered the apparent KI. 
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Table 2-2. Calculated inhibition constants for inhibition of P450 2A activity by 
menthofuran, -nicotyrine and menthola 
Inhibitor 
KI (µM) 
P450 2A6 P450 2A13 
Menthofuran 0.63 ± 0.07 1.17 ± 0.16 
-nicotyrine 1.07 ± 0.02 0.17 ± 0.003 
Menthol 109.5 ± 10.7 8.17 ± 0.86 
a Values are means ± S.D. from three experiments carried out in duplicate.  The inhibition of CYP2A6 
and CYP2A13-mediated coumarin 7-hydroxylation was determined as described in the materials and 
methods.  Curves were generated using non-linear regression analysis. 
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2.3.3 Inactivation 
To compare the relative potential of menthofuran, β-nicotyrine or menthol to 
inactivate either P450 2A6 or P450 2A13, an experiment was carried out at a single 
inhibitor concentration (20 µM). Incubation of P450 2A6 in the presence of NADPH with 
either menthofuran or β-nicotyrine resulted in the loss of coumarin 7-hydroxylation 
activity.  Menthofuran was a particularly potent inactivator; only 5% activity remained 
after ten minutes.  β-Nicotyrine inactivation was more modest with 49% activity 
remaining after ten minutes (Table 2-3). In contrast to the results with P450 2A6, no 
significant loss of P450 2A13 activity was observed with either menthofuran or β-
nicotyrine. Neither increasing the concentrations nor incubation time resulted in any 
significant inactivation of P450 2A13.  Using concentrations of 100 µM menthofuran or 
200 µM β-nicotyrine and incubation a time of 30 min, no loss of P450 2A13-catalyzed 
coumarin 7-hydroxylation was detected (data not shown). Therefore, menthofuran and β-
nicotyrine-mediated inactivation of P450 2A13 does not occur or it is too minor to detect. 
There was no indication that menthol inactivated either P450 2A6 or P450 2A13 (Table 
2-3). 
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Table 2-3.  Loss of P450 2A activity following incubation with menthofuran, -nicotyrine or 
menthol
a
 
Inhibitor (20 µM) 
% Activity Remaining
b
 
P450 2A6 P450 2A13 
Menthofuran 5 ± 1 91 ± 5 
-nicotyrine 49 ± 10 87 ± 2 
Menthol 97 ± 6 87 ± 11 
a Samples were prepared as described in the Materials and methods.  Reconstituted enzyme was incubated 
for 10 minutes at 30 °C in the presence of 20 µM Menthofuran, -nicotyrine or menthol. 
b Values are means ± S.D. from three experiments.  Percent activity remaining is compared to control 
samples that contained no NADPH. 
  
Inactivation of P450 2A6 by menthofuran and β-nicotyrine was not reversible 
upon removal of unbound small molecules. In three experiments, the P450 2A6-catalyzed 
coumarin 7-hydroxylation activity that remained following menthofuran inactivation (8 ± 
5% relative to a minus NADPH control) was unchanged after the sample was passed 
through a size exclusion column (5 ± 3%). Similarly, the coumarin 7-hydroxylation 
activity of β-nicotyrine inactivated P450 2A6 (34 ± 2%) was not recovered when the 
sample was filtered through the column (29 ± 3%).  
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To assess the potential modification of the heme and apoprotein after inactivation 
of P450 2A6 by menthofuran or β-nicotyrine, two experiments were carried out. In the 
first, inactivated P450 2A6 was quantified by a reduced CO difference spectra and the 
loss in spectrally active enzyme was compared to the loss of 7-hydroxycoumarin activity 
relative to a non-NADPH-treated control. After menthofuran treatment, the 7-
hydroxycoumarin activity remaining was 28.5 ± 1.6%, comparable to the amount of 
spectrally active P450 2A6 enzyme remaining 36 ± 4.6% (Table 2-4). Likewise, after β-
nicotyrine treatment the enzyme activity remaining was the same as the amount of 
spectrally active P450 2A6 remaining (Table 2-4). The second experiment quantified the 
amount of native heme by HPLC analysis. For both compounds, the loss in activity after 
incubation in the presence of NADPH was not accompanied by a loss in native heme, and 
only one peak was observed, indicating no modified heme was present (Figure 2-3). 
These results together with the observed loss in the spectrally quantifiable protein, 
suggest that the inactivation of P450 2A6 by both menthofuran and β-nicotyrine was due 
to modification of the apo-protein. 
The kinetic parameters of menthofuran and β-nicotyrine-mediated P450 2A6 
inactivation were determined (Fig 2-4). The loss in P450 2A6 activity was dependent on 
the concentration of menthofuran or β-nicotyrine and increased with time. The KI for the 
inactivation of P450 2A6 by menthofuran, 2.2 µM, was almost 50-fold lower than that of 
β-nicotyrine, 106 mM. The maximum rate constants for menthofuran- and β-nicotyrine-
mediated inactivation, kinact, were 1 and 0.61 min
-1
, respectively; the t1/2 values were 0.7 
and 1.1 min, respectively.  
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The partition ratio, the number of moles of product formed per mole of enzyme 
inactivated, was determined using the titration method 
104
.  In brief, after complete 
inactivation of P450 2A6 with various concentrations of menthofuran or β-nicotyrine, the 
percentage of remaining P450 2A6 activity at each substrate concentration was plotted 
against the molar ratio of compound to enzyme (Figure 2-5). The intercept between the 
linear regression line obtained at low molar ratios and the horizontal line obtained from 
saturating conditions were extrapolated to the x-axis to yield the partition ratio.  The 
partition ratio was more than threefold lower for β-nicotyrine compared to menthofuran 
(10 and 33, respectively). 
 
Table 2-4. Relationship of P450 2A6 inactivation to spectrally active enzyme levels
a
 
Inactivator Activity Remaining Spectrally active P450 
Menthofuran 28.5±1.6
b 
36±4.6
b 
-nicotyrine 55.5±0.7c 48±7.3c 
a Reconstituted enzyme was incubated for 10 minutes at 30 °C in the presence of 20 µM menthofuran or 
50 µM -nicotyrine.  Control samples contained no NADPH.  The samples were analyzed for the 
coumarin 7-hydroxylation activity and the spectrally active enzyme quantified by reduced CO spectra.  
Values are means ± S.D. of percent coumarin 7-hydroxylation activity and percent spectrally active 
CYP2A6 remaining from three experiments.   
b Values were not significantly different, unpaired T-test p=0.068. 
c Values were not significantly different, unpaired T-test p=0.15. 
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Figure 2-3. HPLC/UV chromatograms of P450 2A6 reactions.  Reconstituted P450 
2A6 was incubated for 10 minutes at 30 °C in the presence of 20 µM menthofuran (A), -
nicotyrine (B) or control (no inhibitor) and analyzed by LC/UV-vis at 405 nm.  Heme 
elutes at 20 minutes. 
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Figure 2-4. Time and concentration-dependent inactivation of P450 2A6 by menthofuran 
(A) and -nicotyrine (B).  Activity remaining refers to coumarin 7-hydroxylation activity 
determined in a secondary reaction. The -nicotyrine concentrations used were 0(), 5(), 
10(), 40() and 80() µM and the menthofuran concentrations used were 0(), 1(), 
2.5(), 5() and 10() µM.  Values are the mean ± S.D. from three independent experiments.  
The insets represent the double-reciprocal plot generated from the slopes of the lines at the 
various concentrations. 
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Figure 2-5. Partition ratio determination for CYP2A6 with -nicotyrine (A) and 
menthofuran (B).  The inactivation was allowed to go to completion, and then coumarin 7-
hydroxylation activity was determined in a secondary reaction as described under Materials and 
Methods.  Values are the mean ± S.D. of three independent experiments performed in duplicate.  
The arrow indicates the intercept used to determine the partition ratio. 
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2.4 Discussion 
 P450 2A6 and P450 2A13 are critical catalysts of nicotine and NNK metabolism.  
It is therefore relevant to characterize potential inhibitors of these enzymes as they may 
aid in smoking cessation and mitigate tobacco-specific carcinogenesis.  In the study 
presented here, the inhibition and inactivation of P450 2A6 and P450 2A13 by the 
tobacco constituents, β-nicotyrine and menthol, were characterized and compared to the 
potent P450 2A6 inactivator, menthofuran. Both compounds inhibited the coumarin 7-
hydroxylation activity of these enzymes. Yet, despite the high degree of similarity 
between P450 2A6 and P450 2A13, the effect of menthol, β-nicotyrine and menthofuran 
on each of these enzymes were quite different. Menthol did not inactivate either enzyme.  
It was a significantly better inhibitor of P450 2A13 than P450 2A6 and as indicated by 
the lower Kd, P450 2A13 bound menthol more tightly than P450 2A6.  β-nicotyrine was 
also a more potent inhibitor of P450 2A13 than P450 2A6, and the Kd of P450 2A13 for 
β–nicotyrine was lower than for P450 2A6.  In addition, β-nicotyrine was an MBI of 
P450 2A6 but not P450 2A13. The well-characterized MBI of P450 2A6, menthofuran, 
was also not an inactivator of P450 2A13. This observed enzyme specific inactivation is 
consistent with the previously reported unique substrate specificity for these enzymes, 
and is likely due to the larger active site and more permissive geometry of P450 2A13 
compared to P450 2A6 
69
. 
Menthol cigarettes are used by the majority of African American smokers (85%), 
but only 10–20% of European Americans (NSDUH report). The prevalence of menthol 
cigarettes among African American smokers was hypothesized to contribute to their 
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higher incidence rate of lung cancer compared to European Americans 
97;98;113
. However, 
the proposed link of menthol cigarette use to lung cancer was strongly refuted by the 
results of a recent prospective epidemiology study 
100
. The conclusion of that study was 
that menthol cigarettes are potentially less harmful, not more, than non-menthol 
cigarettes.  Part of what was driving the original hypothesis was the observation that the 
use of menthol cigarettes affected cigarette smoking behavior and P450 2A6-mediated 
nicotine metabolism 
15
. In the study reported here, menthol was found to be a poor 
inhibitor of P450 2A6 and did not inactivate the enzyme. MacDougall et al. also reported 
that menthol is a weak inhibitor of P450 2A6 
16
. These results suggest that the presence 
of menthol will have little, if any, effect on the rate of nicotine metabolism in humans.  
Supporting this conclusion, Williams et al. found no evidence of modified nicotine intake 
when smokers used menthol cigarettes 
114
. 
The effect of menthol on P450 2A13 has not previously been reported.  Here we 
report that menthol is a modest inhibitor of P450 2A13.  Inhibition of P450 2A13 by 
menthol, which is present in tobacco smoke at much higher levels than NNK, might 
mitigate NNK activation by P450 2A13 in the lung.  This inhibition could contribute to 
the results observed by Blot et al showing that the overall odds ratio of lung cancer is 
significantly lower among menthol compared with non-menthol smokers 
100
.   
β-Nicotyrine, a minor tobacco alkaloid, has previously been reported to inhibit 
nicotine metabolism in rodents. The pretreatment of mice with β-nicotyrine resulted in a 
significant increase in tissue and blood levels of nicotine
101
. In addition, there is evidence 
in rabbit lung cells and microsomes that the metabolism of β-nicotyrine results in the 
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formation of reactive and potentially toxic intermediates
115;116. More recently, β-
nicotyrine has been reported to be the most potent inhibitor of P450 2A6 activity among a 
series of nicotine related alkaloids and metabolites with a Ki of 0.37 µM 
90
.  In support of 
this, we have shown here that β-nicotyrine has a three-fold higher binding affinity for 
P450 2A6 than does nicotine.  The previous study also suggested that β-nicotyrine was a 
mechanism based inactivator and time dependent inactivation was reported, however no 
further characterization of the observed inactivation was provided. Here we have 
confirmed that β-nicotyrine is an irreversible inactivator of P450 2A6 and also provided 
evidence that supports the formation of an apoprotein adduct. Alternatively, the observed 
inactivation could be the result of a tightly bound metabolite not removed by dialysis or 
the conditions of our size exclusion column. 
Both P450 2A6 and P450 2A13 are inactivated during nicotine metabolism 
77
. 
The observed inactivation of both enzymes appears to be mediated by a metabolite of the 
nicotine 5'-iminium ion, that is, nicotine-mediated inactivation requires at least two 
sequential oxidations of nicotine. β-nicotyrine is a urinary metabolite of nicotine in some 
species, and forms from the nicotine 5'-iminium ion in vitro 
108;115
.  We report in Chapter 
3 that β-nicotyrine is formed during P450 2A6-mediated nicotine metabolism.  Here, we 
report that β-nicotyrine is an inactivator of P450 2A6 and hypothesize that inactivation of 
the enzyme by nicotine may be due to the formation and successive metabolism of β-
nicotyrine. Prior to our studies, metabolism of β-nicotyrine by human enzymes, either 
P450 2A6 or P450 2A13, had not been studied.   However, in the rabbit, P450-catalyzed 
metabolism results in the formation of two pyrrolinones that likely form by way of an 
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unstable epoxide of the pyrrole ring. This epoxide is one possible candidate for the 
metabolite that inactivates P450 2A6. Experiments characterizing both P450 2A6 and 
P450 2A13-catalyzed β-nicotyrine metabolism are presented in Chapter 3 and the 
products are described therein. 
Menthofuran and β-nicotyrine irreversibly inactivated P450 2A6 but not P450 
2A13. Consistent with earlier studies of menthofuran inactivated P450 2A6 
105
 our data 
supported the conclusion that modification of the apoprotein, not the heme moiety, is the 
likely mechanism of inactivation. Like β-nicotyrine, menthofuran is metabolized to a 
reactive epoxide that may contribute to protein adduct formation 
48
. Menthofuran is a 
more potent inactivator of P450 2A6, with a higher KI(inact) and a lower t½, than β-
nicotyrine. However, the calculated partition ratio for menthofuran-mediated inactivation 
was 3.5 times higher than for β-nicotyrine-mediated inactivation. Therefore, despite the 
relatively high KI(inact) for β-nicotyrine inactivation of P450 2A6, its oxidation more 
frequently generates a reactive metabolite that inactivates P450 2A6 than does 
menthofuran.   
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2.5  Conclusion 
In summary, β-nicotyrine but not menthol is likely to impact nicotine metabolism 
and possibly NNK metabolism in smokers. Menthol was a modest inhibitor of P450 2A6 
and P450 2A13. Whereas β-nicotyrine, which is present in tobacco or generated as a 
metabolite of nicotine, was an effective inhibitor of both P450 2A6 and P450 2A13. More 
importantly, β-nicotyrine inactivated P450 2A6, the primary catalyst of nicotine 
metabolism. Interestingly, neither β-nicotyrine nor menthofuran, the potent mechanism 
based inactivator of P450 2A6, are inactivators of P450 2A13.  
Experiments are on-going to characterize the mechanistic basis for this, since it 
may be useful in the design of P450 2A6 inhibitors and help to elucidate the pathway 
responsible for the inactivation of P450 2A6 by nicotine. 
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Chapter 3 
P450 2A catalyzed β-nicotyrine metabolism and β-
nicotyrine as a metabolite of P450 2A6 catalyzed 
nicotine metabolism. 
 
3.1 Intro 
Nicotine is the major pharmacologically active and most abundant alkaloid found 
in tobacco and thus, has been extensively studied.  There are a number of related 
alkaloids in tobacco that are present at small quantities relative to nicotine, which have 
been subject to much less study (Table 3-1).  One of these alkaloids, β-nicotyrine, is also 
reported to be generated during pyrolysis 
41
.  We have recently confirmed that β-
nicotyrine is a mechanism-based inactivator (“suicide” inhibitor) of P450 2A6, the 
primary catalyst of nicotine metabolism 
117
.  Pharmacologically blocking nicotine 
metabolism has been reported to reduce the extent of smoking 
88;89
.  Therefore, if 
compounds in tobacco block nicotine metabolism, characterizing the exposure of 
smokers (and other tobacco users) to these compounds is critical to understanding their 
influence on the continued use of tobacco.   
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Table 3-1: Alkaloids found in tobacco and their estimated amounts in tobacco 
smoke. 
Compound Structure Amount (mg)
Nicotine 0.8-2.85a,b
β-nicotyrine 0.004- 0.04b
Anabasine 0.002- 0.02b
Anatabine 0.002-0.02a,b
Nornicotine 0.25a
Myosmine 0.013-0.033b
a Pakhale et. Al., 1998 42
b Baker et. al., 1999 41
 
The primary pathway of nicotine metabolism is conversion to cotinine.  The first 
step is the P450-catalyzed 5'-oxidation of nicotine (Figure 3-1).  The nicotine 
Δ5'(1')iminium ion (iminium ion) product of this reaction is then further oxidized to 
cotinine.  This oxidation may be carried out by the cytosolic enzyme aldehyde oxidase 
34
.  
However, P450 2A6 and P450 2A13 also catalyze this reaction
72;
 
68
.  In smokers, P450 
2A6 in the liver is the primary catalyst of the metabolism of nicotine to cotinine.  
Cotinine can then be further oxidized to 3'-hydroxycotinine or 5'-hydroxycotinine 
118
.  In 
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urine of smokers with typical P450 2A6 activity, the summation of cotinine and 
subsequent cotinine metabolites account for more than 80% of a consumed nicotine 
dose
34
. 
Figure 3-1: Nicotine oxidation to cotinine, 3'-hydroxycotinine and 5'-hydroxycotnine. 
 
Several years ago, it was reported that nicotine inactivated both P450 2A6 and the 
closely related enzyme, P450 2A13.  More specifically, as nicotine was metabolized, 
enzyme activity was lost 
77
.  The observed inactivation was dependent on NADPH, time 
and nicotine concentration 
117
.  Additionally, inactivation is observed when the iminium 
ion is metabolized to cotinine.  This lead to the suggestion that the species responsible for 
the observed nicotine inactivation was generated from the nicotine Δ5'(1')iminium ion.  
Knowing that β-nicotyrine metabolism results in inactivation of P450 2A6, we 
hypothesized that β-nicotyrine is a nicotine metabolite that plays a role in nicotine-
mediated inactivation of P450 2A6.  Specifically, we expect that β-nicotyrine is an 
intermediate found during P450 2A6-mediated nicotine metabolism and that subsequent 
metabolism of β-nicotyrine would then lead to the inactivation of the enzyme. 
 Little is known of β-nicotyrine metabolism in smokers, however previous in vitro 
studies have indicated that β-nicotyrine is metabolized rapidly by rabbit, guinea pig, 
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mouse and rat liver homogenates in a process requiring NADPH and molecular oxygen 
119.  Furthermore, unchanged β-nicotyrine could not be detected in the urine of humans 
following a 2 mg oral dose, suggesting β-nicotyrine is metabolized extensively in humans 
119
.   
 The metabolism of β-nicotyrine by rabbit liver and lung has been studied 48;115 and 
a pathway for its metabolism has been proposed (Figure 3-2).  β-nicotyrine was converted 
to two pyrrolinones (1-methyl-5-(3-pyridyl)-3-pyrrolin-2-one and 1-methyl-5-(3-
pyridyl)-4-pyrrolin-2-one) (4, 5), which easily decompose through autooxidation to the 
hydroxypyrrolinone (5-hydroxy-1-methyl-5-(3-pyridinyl)-3-pyrrolin-2-one) (6).  The 
pyrrolinone metabolites are likely formed by way of an epoxide.  Chemical and spectral 
data have implicated 2-hydroxy-β-nicotyrine as a key intermediate (3).  Under acidic 
conditions, the pyrrolinones have been shown to undergo hydration to form 5'-
hydroxycotinine (7).  The epoxide may contribute to the β-nicotyrine-mediated 
inactivation of P450 2A6 that we have reported 
117
.   
 The aim of this study was two-fold: to determine if β-nicotyrine is a metabolite of 
P450 2A6 or P450 2A13-mediated nicotine metabolism and to characterize β-nicotyrine 
metabolism by P450 2A6 and P450 2A13. 
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Figure 3-2.  Proposed pathway for β-nicotyrine metabolism 
 
3.2 Materials and Methods 
3.2.1 Chemicals 
[
3
H]-β-nicotyrine (3H on the pyridine ring, non-specific position) (20 Ci mmol-1, 
99% purity) was purchased from American Radiolabeled Chemicals (St. Louis, MO).  
Nicotine Δ5'(1') iminium ion was synthesized as described previously (Peterson et al., 
1987).  5'-Hydroxycotinine, cis- and trans-3'-hydroxycotinine, and [CD3]-cotinine 
(cotinine-D3) were purchased from Toronto Research Chemicals Inc. (North York, ON, 
Canada). All other chemicals and reagents were purchased from Sigma-Aldrich (St. 
Louis, MO).   
 
(1) (2) (3) 
(4) 
(5) 
(6) 
(7) 
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3.2.2 Enzymes 
Rat NADPH-P450 oxidoreductase and P450 2A6 and P450 2A13 were expressed 
in Escherichia coli and purified as previously described 
68;120
.   P450 2A6, P450 2A13 
and oxidoreductase were reconstituted in the presence of lipid for 45 min at 4 °C. Then, 
50 mM Tris buffer, pH 7.4 and catalase were added to give a final P450 to reductase ratio 
of 1:1, 0.2 µg lipid/pmol P450, and 60 U/µl catalase. 
 
3.2.3 Metabolism of nicotine and iminium ion 
 Nicotine or iminium ion (5 or 200µM) was incubated with reconstituted P450 
2A6 or P450 2A13 (0.25 or 1 µM) in a final volume of 50µl.  Reactions were initiated by 
the addition of a NADPH-generating system (0.4 mM NADP+, 100mM glucose-6-
phosphate, and 0.4 units ml-1 glucose-6-dehydrogenase), were incubated for 0, 1 or 12 
minutes at 37°C then terminated by the addition of 5 µl 15% trichloroacetic acid.     
 
3.2.4 Metabolism of 
3
H-β-nicotyrine  
Total β-nicotyrine metabolism was determined using 3H-β-nicotyrine and 
radioflow HPLC analysis.  The method used was a modification of a previously described 
HPLC system (Chapter 2).  For product determination, reconstituted P450 2A6 or P450 
2A13 (1 µM) were incubated with 20 µM 
3
H-β-nicotyrine (50 µCi mmol-1), 100 mM Tris 
buffer (pH 7.4), NADPH-generating system (0.4 mM NADP+, 100 mM glucose-6-
phosphate, and 0.4 units ml
-1
 glucose-6-dehydrogenase) in a final volume of 200 µl for 5 
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minutes at 37°C.  Similar conditions were used to determine kinetic parameters however 
less P450 (0.2 µM) and varied amounts of 
3
H-β-nicotyrine (0.25, 0.5, 0.75, 1, 2, 5, 10 or 
20 µM) were allowed to incubate for shorter times (30 sec).  The short reaction time for 
kinetics experiments was chosen to minimize the occurrence of inactivation.  Reactions 
were terminated by addition of 20 µl 15% trichloroacetic acid.  All analyses were 
conducted in triplicate.  Products were analyzed by radioflow HPLC with a Phenomonex 
Gemini C18 (5µm, 250 x 4.60 mm) column.  A flow rate of 1 ml min
-1
 was used.  
Compounds were separated using a linear gradient of aqueous 20 mM ammonium 
bicarbonate (pH 7.4) (A) and acetonitrile (B).  The gradient moved from 96% A: 4% B to 
94% A: 6% B in 20 min, then 80% A: 20% B in 10 min, 65% A: 35% B in 5 min, 60% 
A: 40% B in 5 min and held at 40% B for 5 additional min.  Radioactive compounds 
were detected using a β-RAM radioflow detector (IN/US Systems, Tampa, FL) with a 
scintillant flow rate of 2.4 ml min
-1
 [Monoflow 5, National Diagnostics, Atlanta, GA].  
To assess product stability, a single sample was analyzed multiple times over a period of 
20 hours.  During the time between analyses, samples were kept in a closed tube at room 
temperature.   
Radioactive peaks were collected and concentrated under nitrogen.  Samples were 
re-injected to assess purity. A portion of each of the collected metabolites were placed in 
acidic conditions (pH 1) by addition of 30 µL of concentrated hydrochloric acid and 
allowed to incubate for 3 hours at room temperature.   The collected, 
3
H-labeled products 
were co-injected with β-nicotyrine, 5'-hydroxy cotinine, 3'-hydroxy cotinine standards, 
detected by absorbance at 260 and 284 nm.   
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 After determination of [
3
H]-analyte retention times by radioflow HPLC, a sample 
generated using identical conditions but non-radioactive β-nicotyrine was injected and 
metabolites were collected.  Each collected fraction was concentrated under nitrogen and 
major products in collected fractions were determined by LC-MS (as described below).  
Subsequent product ions were identified by LC-MS/MS of the precursor ion (as described 
below).   
 
3.2.5 LC-MS and LC-MS/MS analysis of β-nicotyrine metabolites  
LC-MS/MS analysis was performed on an Agilent 1100 series capillary HPLC 
system (Agilent Technologies) interfaced to a Thermo Fisher Scientific Vantage triple 
quadrupole mass spectrometer (Thermo Fisher Scientific). The samples (2–8 μl) were 
injected onto a Zorbax SB-C18 0.5 mm × 150 mm, 5 μm particle size (Agilent 
Technologies). 
Compounds were eluted with a gradient that held at 99.9% water (0.1% formic 
acid) for five minutes, followed by a linear gradient from  99.9% water (0.1% formic 
acid) to 69.9% water: 30% acetonitrile: 0.1% formic acid in 20 minutes at a flow rate of 
15 μl/min. The column was operated at 40 °C. For the first 2.5 minutes, the eluant was 
diverted to waste before directing the flow into the source of the mass spectrometer. 
LC-MS and LC-MS/MS were performed on the same system under similar 
conditions.  The ESI source was operated in the positive ion mode with a collision energy 
of 25 or 30 V, the s-lens RF amplitude of 75, the collision gas pressure set to 1.0 mTorr 
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and the source CID collision energy set to 25-30V. For LC-MS/MS, selected reaction 
monitoring (SRM) of the mass transitions for the various analytes were used for 
identification. The scan width was 0.30 (m/z) and the scan time 0.05 s and the peak 
widths for Q1 was 0.50 and Q3 was 0.70.  The mass transitions were as follows: nicotine 
(m/z 163 → 130 and m/z 163 → 117), cotinine (m/z 177 → 98 and m/z 177 → 80), β-
nicotyrine (m/z 159 → 117 and m/z 159 → 144), Isomeric pyrrolinones of β-nicotyrine 
(m/z 175 → 117 and m/z 175 → 132), β-nicotyrine hydroxypyrrolinone(m/z 191 → 80 
and m/z 191 → 132), and 5'-hydroxycotinine (m/z 19380, m/z 193134 and m/z 
193149) 
3.2.6 Quantification of cotinine and β-nicotyrine 
 A standard curve was generated from independent solutions of increasing 
concentrations of cotinine (0.125-5 µM) that contained 1 µM cotinine-D3.  The same 
amount of cotinine-D3 was added to each sample.  Eight microliters of each standard or 
sample were injected on the instrument.  Cotinine was quantified by comparing the peak 
area ratios of cotinine/cotinine-D3 to those generated from the standard curve.  β-
Nicotyrine internal standard is not available.  Therefore, a standard curve of β-nicotyrine 
(1-50 nM) was prepared with cotinine-D3 (1 µM) and β-nicotyrine was quantified in a 
similar manner to cotinine (Figure 3-2).  This method was validated as cotinine and β-
nicotyrine responses were linear within the range of concentrations used in the standard 
curves.   
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3.2.7 Data Analysis 
 Km and Vmax values were determined using the Sigma Plot kinetics program from 
Systat Software Inc. (Chicago, IL).  Statistical differences between mean Km or Vmax 
values were determined using a Chi square test. 
 
3.3 Results 
3.3.1 Nicotine and Iminium Ion Metabolism 
To determine if β–nicotyrine is a metabolite of nicotine or iminium ion, complete 
reaction mixtures generated from each of these compounds by either P450 2A6 and P450 
2A13 were analyzed by LC-MS/MS.  By monitoring mass transitions for β–nicotyrine, 
we have confirmed that β–nicotyrine is generated during the P450 2A6-mediated 
metabolism of nicotine and iminium ion in an NADPH-dependent manner (Figure 3-3, A 
and B, respectively).  Retention time and relative abundance of the two mass transitions 
were identical to β–nicotyrine standard (Figure 3-3, C).  The amount of standard in 
Figure 3-1, C is low (1 fmol) to illustrate the limit of quantification.  In contrast, no β–
nicotyrine was detected during the P450 2A13-mediated metabolism of either nicotine or 
iminium ion (Figure 3-3, D and E respectively) suggesting that none was formed or it was 
present at lower amounts than could be detected in low-level standards with the level of 
background present in control samples (Figure 3-3, F).  
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Fig 3-3. LC/MS-MS analysis of nicotine metabolites generated by P450 2A6.  LC-MS/MS 
analysis for m/z showing m/z 159 117 and 159144 mass transitions from P450 2A6-mediated 
nicotine (A) and iminium ion (B) metabolism, the 1 fmol β–nicotyrine standard (C), P450 2A13-
mediated nicotine (D) and iminium ion (E) metabolism and a P450 2A6 control sample that 
contained no NADPH (F). 
 
Using a standard curve normalized to cotinine-D3 used as an internal standard in 
the reactions, the amount of β–nicotyrine generated during P450 2A6-mediated nicotine 
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and iminium ion metabolism was quantified (Figure 3-4).  Formation of β–nicotyrine  
was dependent on time, NADPH and P450 2A6 concentration (Table 3-2 A).  Under the 
conditions used, the amount of β–nicotyrine generated was between 2% and 12% of the 
cotinine generated in the same experiment (Table 3-2 A and B). 
 
Fig. 3-4 Standard curve used to quantify -nicotyrine.  1 µl of β-nicotyrine standards 
(1, 3.125, 6.25, 12.5, and 25 nM) containing 10µM d
3
-cotinine were used to generate 
standard curve. 
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Table 3-2. Amounts of -nicotyrine and cotinine generated during P450 2A6-
mediated  nicotine or iminium ion metabolism. 
Substrate
β–nicotyrine/P450 2A6
(fmol/pmol)
Time (min)
1 12
Nicotine (200 µM) 10.4 183.6
Nicotine (5 µM) ND 12.0
Iminium Ion (200 µM) 17.4 141.8
Iminium Ion (5 µM) ND 47.2
Substrate
Cotinine/P450 2A6
(fmol/pmol)
Time (min)
1 12
Nicotine (200 µM) 78.9 767.2
Nicotine (20 µM) ND 137.0
Iminium Ion (200 µM) 537.6 1946.5
Iminium Ion (20 µM)
231.4 839.4
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Figure 3-5.  Radioflow HPLC analysis of P450 2A6 catalyzed metabolism of β-nicotyrine.   
P450 2A6 was incubated with β-nicotyrine in the presence (solid line) or absence (dashed line) of 
NADPH.   
 
3.3.2 P450 2A6 and P450 2A13-mediated β-metabolism 
The relative metabolism of 
3
H-β-nicotyrine by P450 2A6 and P450 2A13 was 
analyzed by radioflow HPLC.  P450 2A6-mediated metabolism of β-nicotyrine resulted 
in four radioactive peaks.   The peak with an elution time of 38 minutes appeared in the 
control sample and was time-dependent but not NADPH-dependent.  The peak with a 
retention time of 26 minutes eluted very close to a peak that also appeared in the control 
sample.  Five-second fraction collection of the time spanning this peak and subsequent 
LC-MS/MS analysis of these fractions demonstrated that the compound in the control 
sample that appears at 26 min was also present in the metabolized sample but was distinct 
from product (b).  Therefore, the shoulder seen on the left side of peak (b) was not a 
metabolite and was excluded from quantification (Figure 3-5).  Thus, three product peaks 
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(retention times were 23 min (a), 26 min (b) and 32 min (c)) were considered for further 
analysis.  Metabolite a co-eluted with the 5'-hydroxycotinine standard (data not shown).  
P450 2A13-mediated metabolism of β-nicotyrine generated the same metabolites. 
It was observed that the relative amounts of the metabolites formed during 
identical experiments carried out on different days resulted in inconsistent product ratios.  
It became obvious that the product ratio variation was dependent upon the time between 
reaction termination and sample analysis.  Therefore, to assess product stability, a sample 
was allowed to sit at room temperature in capped tubes before analysis. After five hours, 
the amount of metabolite c decreased and the amount of a and b increased (Figure 3-6). 
This indicates that non-enzymatic conversion of metabolite c to a and b is occurring.   
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Fig 3-6. Radioflow HPLC analysis of -nicotyrine metabolites.   . A. Control Sample (-NADPH) is 
shown in panal (A) and sample containing metabolites (a), (b) and (c) either 0 hours (solid line ) and 5 
hours (dashed line) at room temperature.  
 
After determination of [
3
H]-analyte retention times by Radioflow HPLC, a sample 
was injected a second time and fractions were collected for the [
3
H]-metabolites (a), (b) 
and (c) elution times.   A similar but non-radioactive sample was also injected and, based 
on retention time, metabolites (a), (b) and (c) were collected.  These collected samples 
were used to further characterize the three product peaks.  Additionally, a portion of the 
non-radioactive reaction was analyzed directly by LC-MS.  This analysis identified four 
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metabolite peaks.  Mass to charge ratios for each of these were m/z 159, m/z 175, m/z 191 
and m/z 193.    
Several pieces of evidence indicate that metabolite a is 5'-hydroxycotinine.  First, 
as mentioned above, a co-eluted with 5'-hydroxycotinine standard during  
LC/Radioflow/UV analysis.  Secondly, collected metabolite peak a had a m/z of 193 
(Figure 3-9, A) which is consistent the molecular weight of 5'-hydroxycotinine.  Finally, 
when an LC-MS/MS trace of a is compared to that of the 5'-hydroxycotinine standard, 
retention time and relative abundance of mass transitions are identical (Figure 3-7).  5′-
Hydroxycotinine is in equilibrium with 4-(3-pyridyl)-4-oxo-N-methylbutyramide (keto 
amide) (Figure 3-8) that eluted as separate peaks (retention times 3.7 and 5.2 min).  Both 
peaks are detected in collected metabolite a and the standard.  The keto amide has two 
major fragments (m/z 19380, m/z 193134).  Major fragments of 5'-hydroxycotinine 
include the two that are observed for the keto amide as well as an additional fragment at 
m/z 193149 (Figure 3-9, A, inset).   
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Figure 3-7. LC-MS/MS of 5'-hydroxycotinine  and collected metabolite a.  LC-MS/MS using 
SRM of 5'-hydroxycotinine standard (A-C) and collected metabolite a (D-F).  Mass transitions 
monitored are m/z 19380 (A,D), m/z 193134 (B,E) and m/z 193149 (C,F).   
 
-C2H4O  44 
 
Figure 3-8. 5'-hydroxycotinine in equilibrium with the keto amide.  Dotted line indicates 
bond breaking resulting in m/z 149. 
 
The parent ion for metabolite b was m/z 191 (Figure 3-9, B).   This is the mass of 
the hydroxypyrrolinone (6) (Figure 3-2) consistent with the identification of it as a 
metabolite of β-nicotyrine that underwent two oxidations.  Product ion spectra from m/z 
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191 [M - H]
+
 contained the protonated pyridine fragment, m/z 80.  Because the pyridine 
ring is present in all of the proposed metabolites of β-nicotyrine,   this fragment is not 
diagnostic (Figure 3-9, B inset).   
The mass of metabolite c had a precursor m/z of 175, corresponds to the mass of a 
β-nicotyrine metabolite that underwent one oxidation (Figure 3-9, C).  One oxidation of 
β-nicotyrine generates the 2-hydroxy-β-nicotyrine (3) or the isomeric pyrrolinones 
(Figure 3-2, 4 and 5).  The product ion spectra from m/z 175 [M - H]
+
 contained four 
major fragments (Figure 3-5, inset).  Two of these fragments support the identification of 
c as the pyrrolinones; the m/z 118 corresponding to the loss of C2H2NO and the m/z 147 
corresponding to the loss of CO are generated from either of the pyrrolinones (Figure 3-9 
C).   
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Figure 3-9. LC-MS/MS analysis of collected β-nicotyrine metabolites a, b and c.  Total ion 
chromatographs are shown with parent masses labeled next to the major product peak.  MS/MS 
spectra are shown as insets. 
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 A fraction of [
3
H]-metabolite c was incubated at room temperature under acidic 
conditions.  When re-injected on the HPLC system, the analyte peak co-eluted with the  
5'-hydroxycotinine standard (Figure 3-10).  Based on previous work by Liu et al, 1999 
and the relevant chemistry, this conversion of metabolite c to 5'-hydroxycotinine further 
supports the identity of c as a pyrrolinone 
48
.   
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Fig 3-10. Radioflow HPLC analysis of metabolite (c) with and without acid. Collected [
3
H]-
metabolite (c) was either analyzed by HPLC/Radioflow (Top panel, solid line) or incubated in 
acidic conditions analyzed by HPLC/Radioflow (bottom panel, solid line).  Samples in both cases 
were co-injected with 5'-hydroxycotinine and monitored by UV (260 nm) (dashed lines). 
 
 
Due to the conversion of metabolite c to metabolite a and the variability in 
quantification of metabolite b due to its autooxidation from metabolite c, all three 
products were summed to determine the rate of the initial β-nicotyrine oxidation.  Kinetic 
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constants were determined for both P450 2A6 and P450 2A13-mediated metabolism of β-
nicotyrine (Figure 3-11).   Both P450 2A6 and P450 2A13 metabolized β-nicotyrine very 
quickly as indicated by the relatively high Vmax values (21 and 37 pmol 
product/min/pmol, respectively).  The calculated Km values for P450 2A6 and P450 
2A13-mediated β-nicotyrine metabolism (4.4µM and 5.0µM, respectively) are similar to 
the reported Km for coumarin 7-hydroxylation (6.0 µM and 3.7 µM, respectively 
75;111
.   
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Fig 3-11. P450 2A6 and P450 2A13-mediated metabolism of β-nicotyrine.  Kinetic curves for 
P450 2A6-mediated (Left) and P450 2A13-mediated (Right) metabolism of  β-nicotyrine. 
 
3.4 Discussion 
 Assessing a smoker's exposure to β-nicotyrine and understanding its subsequent 
influences on smoking behavior are necessary to gauge if this compound ought to be 
monitored in tobacco products.  Additionally, knowing the mechanism of the observed β-
nicotyrine-mediated P450 2A6 inhibition could aid in the design of a drug for smoking 
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cessation.  This study set out to determine if exposure could occur due to the generation 
of β-nicotyrine from nicotine and characterize the P450 2A-mediated metabolism of β-
nicotyrine. 
β-Nicotyrine is metabolized to the same products by both P450 2A6 and P450 
2A13.  Three products were identified; two of them form as a result of decomposition of 
the first.  Evidence supporting the primary metabolite as a mixture of two isomeric 
pyrrolanones (4 and 5) is presented here (Figure 3-2).  This finding is supported by 
previous work that identified these compounds as metabolites of β-nicotyrine in rabbit 
liver and lung microsomes 
48;115
.  One of the two decomposition products is likely 5-
hydroxyl-1-methyl-5-(3-pyridinyl)-3-pyrrolin-2-one (6) and the other is 5'-
hydroxycotinine (7).  While we have shown here that 5'-hydroxycotinine can form by 
autooxidation of the pyrrolanones (4 and 5), our work does not exclude the possibility 
that it is also formed by P450-mediated oxidation.  This distinction matters with regard to 
the accuracy of the calculated kinetic parameters of the initial β-nicotyrine oxidation.  In 
an ideal world, synthesized pyrrolinone could be incubated with P450 2A6 or P450 2A13 
to determine if it is a substrate for these enzymes, however there are two problems with 
this experiment.  The first is a practical issue.  While it is possible to synthesize a mixture 
of the pyrrolinones, they are chemically unstable and therefore would be difficult to 
quantify and use before decomposition occurred 
48
.  One must consider the mechanism of 
substrate turnover to understand the second issue.  Catalysis of sequential oxidations, 
where the substrate does not leave the active site, is not unusual in cytochrome P450 
reactions.  Sequential oxidation is seen with P450 2A6-mediated nicotine and 
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diethylnitrosamine metabolism
121-123
.  If sequential oxidation occurs during P450 2A6-
mediated β-nicotyrine metabolism, the rate of pyrrolinone metabolism would not include 
binding of the substrate to the enzyme.  Kinetic parameters generated from an experiment 
that started with the pyrrolinone would include this, possibly limiting, binding step. 
β-Nicotyrine is generated during P450 2A6-mediated metabolism of nicotine and 
iminium ion.  Here we have estimated that the amount of β-nicotyrine generated is 
between 3% and 24% of the cotinine generated.  While this number is to be considered an 
estimate, as it does not account for subsequent metabolism of β-nicotyrine or cotinine, a 
rough extrapolation can be made to an in vivo situation.  Assume a smoker took in 1 mg 
(5.6 µmol) of nicotine per cigarette and 80% of that was converted to cotinine.  This 
leaves 4.5 µmol of cotinine. If the amount of β-nicotyrine generated is three percent of 
the cotinine, 136 nmol of β-nicotyrine would be generated per cigarette.  According to the 
partition ratio calculated for β-nicotyrine inactivation of P450 2A6 117, ten percent of that 
would lead to inactivation.  Loss of 13 nmol of P450 2A6 activity could have a 
significant impact on nicotine metabolism and subsequent smoking behavior.  Albeit, this 
assumes optimal conditions and a linear relationship between in vitro to in vivo work, it 
has been included to highlight that further study of β-nicotyrine impact on nicotine 
metabolism is warranted. 
 It is curious that β-nicotyrine was not detected during P450 2A13-mediated 
metabolism of nicotine or iminium ion.  The simple explanation for this would be that no 
β-nicotyrine is generated during P450 2A13-catalyzed nicotine metabolism.  While there 
is a high degree of similarity between these two enzymes, there are examples where they 
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generate different products or product ratios from the same substrate.  One well-
characterized example of this is P450 2A6 and 2A13-mediated coumarin metabolism.  
P450 2A6 solely generates 7-hydroxycoumarin whereas P450 2A13 produces 7-
hydroxycoumarin and the coumarin 3,4-epoxide 
75
.  Another example of a difference 
between these two enzymes is cotinine metabolism.  While norcotinine is the major 
product of P450 2A6-mediated cotinine metabolism, it is a very minor product of P450 
2A13-catalyzed cotinine metabolism 
124.  It stands to reason that, if β-nicotyrine is a 
much more minor product of P450 2A13-mediated than P450 2A6-mediated nicotine 
metabolism,  and we know that β-nicotyrine is rapidly metabolized by P450 2A13, any β-
nicotyrine generated would be so rapidly turned over it would likely be missed under the 
conditions of our analysis.  A follow up experiment looking for the β-nicotyrine 
pyrrolinones, hydroxy-pyrrolinones and 5'-hydroxycotinine during P450 2A13-mediated 
nicotine metabolism would distinguish between these two explanations.  
 
3.5 Conclusion 
While the metabolic differences between P450 2A6 and P450 2A13 are 
interesting with regard to our understanding of structure-function relationships in P450 
active sites, the big picture relevance of this study is the impact β-nicotyrine may have on 
P450 2A6-mediated nicotine metabolism.  P450 2A6 is primarily responsible for nicotine 
metabolism in vivo. The identification of β-nicotyrine as a product of this metabolism 
combined with the knowledge that it inactivates P450 2A6 is novel, could potentially 
impact nicotine metabolism and thus, could be useful in nicotine cessation products. 
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Chapter 4 
 
Protein modification during inactivation 
 
4.1 Introduction 
P450 inhibitors can be categorized as reversible (competitive or noncompetitive), 
quasi-irreversible, or irreversible in nature.  Reversible inhibition usually involves two or 
more compounds competing for binding at the active site of a P450, with one compound 
inhibiting the metabolism of the other.  In contrast, irreversible P450 inhibitors are 
catalytically converted to electrophilic reactive metabolites that may interact with the 
P450 quasi-irreversibly or irreversibly leading to enzyme destruction 
104
.  The inactivated 
P450 is catalytically incompetent and must be replenished by newly synthesized protein. 
The phenomenon is referred to as time-dependent inhibition, mechanism-based 
inactivation (MBI), and/or suicide inactivation.  It should be noted that not every turnover 
of the inhibitor in question leads to inactivation of the enzyme; generation and release of 
product can still occur a percentage of the time (Figure 4-1).  The accepted model is that 
inactivation occurs due to a covalent bond formed between the reactive species and the 
enzyme, however, a very tight-binding intermediate could also fit the criteria for MBI 
104
.  
If the mechanism of inactivation is through a covalent modification, the modification 
could be on either the heme or the apoprotein.   
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MBI has been useful in the design of potential drugs.  Most enzyme inhibitor 
drugs are reversible inhibitors and so the basis for their effectiveness is the tightness of 
their binding to the P450.  The effectiveness of the drug continues as long as enzyme is 
complexed with the drug.  Because the enzyme concentration is low and fixed, the 
equilibrium between complexed and non-complexed drug will depend on the 
concentration of drug and the competing substrate.  Concentration of drug will diminish 
due to metabolism and excretion; concurrent with this, the concentration of enzyme in 
complex with substrate will increase.  Therefore, to maintain effective P450 inhibition, 
the drug must be re-administered.  A drug that acts as a mechanism-based inactivator, 
however, could form a covalent bond to the enzyme, thereby preventing the dissociation 
of the inactivator from the enzyme, allowing for less-frequent and lower dosing of the 
drug.  This is particularly appealing as most adverse drug reactions correlate with high 
therapeutic doses
125
.  Unwanted inactivation, however, needs to be considered carefully.  
Compared to reversible P450 inhibition, drug-induced MBI of P450s presents a greater 
safety concern because of the increased propensity for drug-drug interactions upon 
Figure 4-1.  Representative pathway  to mechanism based 
inactivation.  Enzyme (E) binds to Mechanism Based Inactivator (MBI), 
converts MBI to reactive intermediate (MBI**) that can subsequently be 
converted to product (P) or irreversibly bind to the enzyme (EMBI**). 
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multiple dosing and the sustained duration of these interactions after discontinued 
administration of the mechanism-based inactivator
126
.   
Pharmacologically inhibiting the activity of P450 2A6, the P450 responsible for 
nicotine metabolism, has been shown to decrease the rate of nicotine elimination and 
subsequently can reduce the extent of smoking 
88;89
  The identification of a mechanism-
based inactivator specific to this enzyme could provide a very strong drug candidate for 
smoking cessation.  We have previously reported that nicotine, nicotine
Δ1',5'
iminium ion 
or β-nicotyrine metabolism results in inactivation of P450 2A6 77;117.  We have shown 
that β-nicotyrine is generated during nicotine metabolism (Chapter 3 of this thesis) 
leading to the hypothesis that inactivation of P450 2A6 during nicotine and β–nicotyrine 
metabolism is related. β–Nicotyrine metabolism by P450 2A6 has been studied; two 
isomeric pyrrolinones and hydroxyl-pyrrolinone of β–nicotyrine have been identified as 
products (Chapter 3 of this thesis). 
As inactivation controls, two known MBIs of P450 2A6 are used in this study;  
menthofuran, which has been identified as a potent mechanism based inactivator of P450 
2A6 and 8-Methoxypsoralen (8-MOP), a known inactivator of P450 2A13 and P450 
2A6
106;107
.  Menthofuran-mediated loss of P450 2A6 activity was dependent on catalytic 
turnover and immunohistochemistry analysis provided evidence that the apo-protein was 
modified 
105
.  In addition to demonstrating that 8-MOP-mediated inactivation of P450 
2A13 was dependent on catalytic turnover and time, mass-spectral evidence of a covalent 
adduct to the protein was presented.  Furthermore, in humans, ingestion of 8-MOP 
directly reduces smoking in a laboratory setting 
88
. 
77 
 
In this study, we aim to begin elucidating the chemistry involved in β-nicotyrine-
mediated inactivation of P450 2A6.  Identifying the mass of a covalent modification and 
the site of adduction is related to the catalytic mechanism of the enzyme and can help in 
this aim.   
 
 
4.2 Materials and Methods 
 
4.2.1 Chemicals and Enzymes 
Optima® grade acetonitrile was purchased from Fisher Chemical (Fair Lawn, 
NJ). Sequencing grade modified trypsin was purchased from Promega (Fitchburg, WI).  
β-nicotyrine [3H(G)]-β-nicotyrine (20 Ci mmol-1, 99% purity) was purchased from 
American Radiolabeled Chemicals (St. Louis, MO).  All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO).The enzymes used in this study were heterologously 
expressed in Escherichia coli and purified as described in Chapter 2 of this thesis. 
 
4.2.2 Inactivation 
P450 2A6 (0.1 nmol) was reconstituted with reductase (0.1nmol) and lipid (5µg) 
for 45 min at 4° C (100 µl total volume).  The primary reaction mixture contained 1 
pmol/ml P450, 1 pmol/ml reductase, 75 ng/ml lipid, 26 U/ml catalase, 20 µM 
menthofuran or 50 µM β-nicotyrine or 20 µM 8-MOP and 1 mM NADPH (water in 
control samples) in 50 mM Tris buffer (pH 7.4) (50 µl total volume). The samples were 
incubated for 5 min at 30 prior to the addition of NADPH. At 5 min following NADPH 
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addition the control (+NADPH, -Inhibitor), exposed (-NADPH, +Inhibitor) and 
inactivated (+NADPH, +Inhibitor) samples (10 pmol P450) were injected on reverse 
phase HPLC and analyzed on the ion trap mass spectrometer. 
Inactivation by 
3
H-β-nicotyrine was carried out under the same  conditions except 
less lipid (10 µg) and β-nicotyrine (20 µM, 1 Ci mmol-1) was used.  After ten minutes 
incubation, samples were injected on a radioflow HPLC with a JupiterProteo4u (250 x 
4.60 mm) column.  A flow rate of 1 ml min
-1
 was used.  Compounds were separated 
using a linear gradient of 0.1% trifluoroacetic acid (A) and acetonitrile (B).  The linear 
gradient moved from 70% A: 30% B to 30% A: 70% B in 35 min.  Radioactivity was 
detected using a β-RAM radioflow detector (IN/US Systems, Tampa, FL) with a 
scintillant flow rate of 2.4 ml min
-1
 [Monoflow 5, National Diagnostics, Atlanta, GA].  
 
4.2.3 Effect of trapping agents 
Effect of trapping agents on inactivation were determined by co-incubating 
menthofuran (5 µM) or β-nicotyrine (20 µM) in the primary reaction mixture (as 
described in above section) with 10 mM glutathione or semicarbazide. The primary 
reaction mixtures were incubated for 10 min before aliquots were added to the secondary 
reaction mixture (as in above section). 
 
4.2.4 Tryptic Digestion  
Inactivated P450 2A6 (as described in 4.2.2) was diluted 1:4 in nanopure water 
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and acetonitrile was added to a final concentration of 10% (v/v) MeCN. The pH of the 
solution was adjusted to 7.5-9.0 by adding 50 mM ammonium bicarbonate containing 1 
mM CaCl2. The lyophilized trypsin was solubilized in 50 mM acetic acid. Trypsin was 
added to the protein solution to a final concentration of ~1:60 protease:protein (w/w) and 
the digestion was allowed to proceed overnight at 37 °C. The samples were cooled to RT 
and the pH was adjusted to 3 with glacial acetic acid (1-5 μL). The digested samples were 
stored at -80 °C until analysis by LC-ESI+-MS/MS. 
 
4.2.5 LC-ESI+-MS analysis of whole protein 
Helium was the nebulizing and drying gas (15 psi, 5 L/min) which had a 
temperature set at 200 °C.  Reverse phase LC was performed on an Agilent 1100 
capillary HPLC with a Zorbax 300SB-C8 (3.5 µm, 150 x 0.3 mm) (Agilent Technologies, 
Santa Clara, CA).  Products were eluted at a constant flow rate of 12µL/min with the 
following gradient: hold at 70% A: 30% B for five minutes; linear gradient to 35% A: 
64% B in ten minutes; linear gradient to 20% A: 80% B in 15 minutes; linear gradient to 
10% A: 90% B in five minutes.  Solvent A was 0.1% trifluoroacetic acid in water (v/v) 
and solvent B was acetonitrile containing 0.1% trifluoroacetic acid. ESI-LC-MS for β-
nicotyrine and 8-MOP-inactivated samples were carried out with an Agilent 1100 series 
LC-MSD Trap SL mass spectrometer operating in positive ion mode. MS scans were 
acquired with the sheath gas set to 90 (arbitrary units) and the auxillary gas set to 30 
(arbitrary units). The spray voltage was 3.5 kV, the capillary voltage 45 V, and the 
capillary temperature was set at 200.  The protein spectra were deconvoluted using the 
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Data Analysis for LC-MSD Trap Version 3.2 (Bruker, Billerica, MA). The mass 
spectrometer is located in the Analytical Biochemistry core facility of the Masonic 
Cancer Center, University of Minnesota.  Menthofuran-treated samples were analyzed in 
a similar manner using an Agilent LC-MSD TOF with reflectron mass spectrometer at 
the Mayo Proteomics Research Center (Rochester, MN). 
 
4.2.6 LC-ESI+-MS/MS analysis of peptides 
Reversed-phase LC was performed with an Eksigent nano LC-Ultra 2D LC 
system (Dublin, CA) equipped with a 10-cm fused silica emitter (75 μm inner diameter 
from New Objective, Woburn, MA) in-house packed with reverse-phase Zorbax SB C18 
5 μm resin (Agilent Technologies, Santa Clara, CA). Products were eluted at a constant 
flow rate of 300 nL/min with the following conditions: 25 min linear gradient from 95% 
A, 5% B to 80% A, 20% B; 25 min linear gradient to 10% A, 90 %B, 10 min hold at 10% 
A, 90% B; 5 min linear gradient to 95% A, 5% B, then a 15 min hold at 95% A, 5% B. 
Solvent A was 0.1% formic acid in water (v/v) and solvent B was acetonitrile containing 
0.1% formic acid. ESI+-MS/MS was performed with a Thermo Scientific LTQ-Orbitrap 
Velos instrument (Thermo Electron, Bremen, Germany) in positive ion mode. General 
mass spectrometric conditions were: electrospray voltage, 1.6 kV; capillary temperature, 
275 °C; no sheath or auxiliary gas flow. Protein digests (1 μL) pre-acidified with glacial 
acetic acid were injected onto the column. MS data were acquired with the Orbitrap 
analyzer at a resolving power of 60,000 at 400 m/z. Nine scan events were used as 
follows: (Event 1) m/z 300-2000 full scan MS and (Events 2-9) data-dependent scan 
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MS/MS on the eight most intense ions from event 1. An isolation window of 2.5 m/z, ion 
selection threshold of 500 counts, activation q = 0.25, and activation time of 30 ms were 
applied for MS2 acquisitions. The spectra were recorded using dynamic exclusion of 
previously analyzed ions for 0.5 min with two repeats and a repeat duration of 0.5 min. 
Ions with unassigned charge states or charge states of <2 were excluded. The MS/MS 
normalized collision energy was set to 35%. All data were processed with the Qual 
browser module of Xcalibur 2.1.0.1139 (Thermo Electron). The lock mass was enabled 
for accurate mass measurements. Polydimethylcyclosiloxane (m/z, 445.120024) ions 
were used for internal calibration. The mass spectrometer is located in the Analytical 
Biochemistry core facility of the Masonic Cancer Center, University of Minnesota.  
 
4.2.7 Data Analysis 
Tryptic digestion MS data were analyzed using Proteome Discoverer 1.3 and 
Xcalibur 2.1 (Thermo Electron). Peak lists and predicted CID fragmentation were 
generated using Proteome Discoverer, while peak areas and actual fragmentation were 
checked in Xcalibur. Precursor ions were required to have a mass tolerance of 5 ppm, 
while fragment ions were required to have a mass tolerance of 0.8 Da. Dynamic 
modifications were searched using Sequest on lysine, cysteine, and alanine residues (as a 
control) or all residues. The monoisotopic modification masses searched were: 149.09663 
(addtition of menthofuran), 103.04219 (identified by mass spectra of whole, β-
nicotyrine–modified P450 2A6), 173.07148 (addition of oxidized β-nicotyrine), and 
189.06639 (addition of twice-oxidized β-nicotyrine). The peptide window for the peak 
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list was set for 300-6000 Da (singly-charged equivalent). The search database consisted 
of the commonly accepted sequence for P450 2A6 except for one substitution in the N-
terminus (L2A) that is present in the enzyme used 
110
.  Xcorr scores and mass deviations 
were used as significance cut-offs. Since alanine cannot be modified, the highest scoring 
peptide with a false alanine modification was used to set the minimum Xcorr score for an 
adducted peptides. Once a peptide was identified, its mass was searched in all of the 
samples. In order for a modification to be considered valid, the peptide must: 1) have 
been identified by the Proteome Discoverer software using the search criteria and 
significance cut-offs listed above in at least one sample, 2) be present as a peak in the 
chromatogram and not in the controls, 3) demonstrate at least two y- and two b-ions that 
match with the predicted fragmentation of that modified peptide.  These search criteria 
were selected after collaborative discussion with Dr. Martin Phillips (ORISE Fellow, 
FDA) who employed similar methods in his research.   
 
4.3 Results 
To investigate P450 2A6 modification by menthofuran or β-nicotyrine, the 
enzyme was incubated with 20 μM menthofuran or 50 μM β-nicotyrine in the presence or 
absence of NADPH.  Two different, complementary techniques were used to detect 
protein modification.  ESI-LC-MS was employed to determine the mass of the adduct as 
well as measure extent of modification. The locations of the modifications were queried 
through high resolution LC-MS/MS analysis of tryptic digests. 
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Proposed modification masses were chosen from two sources, the mass-shifts 
observed from LC-MS experiments of the whole and inactive enzyme (Table 4-1) and 
theoretical masses that were proposed based on suspected chemistry.  Both menthofuran 
and β-nicotyrine are suggested to go through an epoxide intermediate (Figure 4-2, A and 
B).  The proposed menthofuran chemistry mimics known furan chemistry 
127
. 
 
 
 
 
 
 
 
 
 
Figure 4-2. Proposed scheme for menthofuran (A) and β-nicotyrine (B) as mechanism based 
inactivators by lysine modification.  Dotted line indicates possible fragmentation (see page 94). 
 
4.3.1 Protein modification 
ESI-LC-MS of unmodified P450 2A6 gave a mass of 57189.94 Da, which 
corresponds to the hypothetical mass of a menthofuran modification (Figure 4-3 A).  The 
A 
B 
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menthofuran-modified sample had some unmodified P450 2A6 as shown by the peak at 
57188.21 Da (Figure 4-3 C).  In the same sample, evidence of adduct formation to the 
P450 2A6 apo-protein as seen by additional peaks in the deconvoluted spectrum.  Two of 
these, with masses of 57205.28 and 57355.10 Da, are of particular interest (Figure 4-3, 
C).  The first, and the most abundant peak in the deconvoluted spectrum, with a mass of 
57205.28 Da gives a 17 Da mass shift.  Within the mass-accuracy of this instrument, this 
could be the addition of water or an oxygen atom. The second, with a mass of 57355.10 
Da, gives a mass shift of 150 Da which is the expected mass of a menthofuran-generated 
adduct.  Based on the mass shift of the whole protein as well as the proposed chemistry, it 
is likely that the menthofuran-mediated modification has a mass of 150 Da (Figure 4-2, 
A).  Therefore, when menthofuran-modified P450 2A6 samples were digested with 
trypsin and analyzed using high resolution LC-MS/MS, resulting data files were queried 
to look for mass shifts of 150 Da. 
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Figure 4-3. ESI-LC-MS analysis of adduct formation to the P450 2A6 protein upon 
inactivation by menthofuran.  Reconstituted P450 2A6 was incubated with menthofuran (20 
uM) in the presence (inactive sample, A and B) or absence (exposed control, C and D) of 
NADPH (1mM) as described in methods.  Total ion chromatogram of each sample with the 
protein envelope for P450 2A6 shown in the inset (B and D) . Deconvoluted spectrum of the P450 
peak for an exposed control sample (A) and an inactivated sample (C).   
 
 ESI-LC-MS analysis of three samples (control, β-nicotyrine and 8-MOP-modified 
P450 2A6 β-nicotyrine-modified P450 2A6) identified masses that corresponded to 
unmodified P450 2A6.  In the control sample the mass was 57204.5 Da, in the β-
nicotyrine-modified the mass was 57210.2 Da and in the 8-MOP-modified the mass was 
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57206.2 Da.  This gives a variation of ± 6 Da, within the limitations of the instrument 
used. 
0
1
2
3
10 20 30 40
54855
57204.5
53000 57000 61000
m/z
0
1
2
3
In
te
n
s
it
y
(x
 1
0
8
).
57210.2
57405.6
56200 57000 57800
0
1
2 57206.2 57327.4
56200 57000 57800
m/z
m/z
0
Time (min)
1100
m/z
2200
m/z
m/z
600
1100 2200600
1100 2200600
P
4
5
0
 2
A
6 A
B
C
 
Figure 4-4. Total Ion Chromatograph from  8-MOP-inactivated P450 2A6 (A), β-nicotyrine-
inactivated P450 2A6 (B) and β-nicotyrine-exposed control P450 2A6 (C).  Protein envelope are 
shown in the left inset,  deconvoluted spectra are shown in the right inset. 
 
 
ESI-LC-MS analysis of β-nicotyrine-modified samples identified mass shifts from 
the unmodified P450 2A6 (Table 4-1).  Figure 4-4, B is representative of one of the 
observed mass shifts with a mass of 57405.6 Da.  In each of three replicates, a different 
mass shift was observed.  Simply stated, the experiment was done three times and each 
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time, a different result was observed.  None of the mass shifts seen were in agreement 
with any proposed chemistry.  Likely chemistry would include a mass shift of 174 Da 
from addition of the β-nicotyrine epoxide intermediate (Figure 4-2, B) or perhaps a mass 
shift of 190 Da that could result from Michael addition of the hydroxypyrrolinone 
product.  Therefore, when β-nicotyrine-modified P450 2A6 samples were digested with 
trypsin and analyzed using high resolution LC-MS/MS, resulting data files were queried 
to look for the mass shift observed by LC-MS as well as the proposed mass shifts based 
of the addition known metabolites and likely chemistry. 
 
Mass shifts (Da)
β-nicotyrine 8-MOP
Trial 1 195 121
Trial 2 106 232
Trial 3 101 337
Table 4-1. Observed mass shifts on P450 2A6 after 
incubation with either β-nicotyrine or 8-MOP.  
 
An 8-MOP-mediated apo-protein adduct had been previously observed on the 
highly similar enzyme, P450 2A13.  The previously observed 8-MOP adduct had a mass 
of 232 Da.  Much like the results obtained with β-nicotyrine, each of the three times the 
experiment was performed, three different mass shifts were observed.  One of the three 
times, the mass that was previously observed was also observed in our experiment.  The 
two other times mass shifts of 121 and 337 Da were seen.   
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4.3.2 Peptide Searches 
  The locations of adducting fragments were searched by analyzing tryptic digests 
of the reaction mixtures by LC-MS/MS analysis on a LTQ-Orbitrap Velos mass 
spectrometer.  Proteome Discoverer software was employed to determine the location of 
the various P450 2A6 modifications caused by treatment with menthofuran or β-
nicotyrine.  Unmodified peptides were identified in all samples.  Coverage of the protein 
by unmodified peptides ranged from 67%-98% but was typically over 80%.   
Table 4-2 displays results from a data query that looked for an addition of 175 Da 
in a sample that had been treated with β-nicotyrine.  In the β-nicotyrine–P450 2A6 
reaction mixtures, there was no preference, with regard to amino acid residue, for a 
suggested adduct.  It is noted that at similar qualifying parameters, such as Xcorr and 
mass deviations, β-nicotyrine-modifications are suggested to appear on alanine and other 
residues that are unlikely to react with an electrophilic metabolite of β-nicotyrine (Table 
4-2).  Therefore, no adduct identifications fit the criteria outlined in the methods section.  
This is seen with all mass-shifts that were queried for potential β-nicotyrine-
modifications as well as the mass-shift queried for menthofuran-mediated modification of 
P450 2A6. 
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Sequence 
Residue and 
Position XCorr MH+ [Da] 
ΔM 
[ppm] 
DGALTQlNVAFsREQShKVYVQHLLk L7; S12 2.52 3361.74135 -0.83 
IQeEAGFLIDALR E3 2.27 1664.86429 -0.02 
vILGVTIPADSNEKHLQVIGYEKMIHhpHFSVTSIDHDImLIK V1; P28; M40 2.13 5413.81147 1.77 
lHEEIDR L1 1.69 1085.53653 -0.87 
mELFLFFTTVMQNFRLKsSQSpk S18; P22; K23 1.67 3317.66086 -0.94 
hLPGPQQQAfKELqGLEDfIAKK H1; F10; Q14 1.51 3002.55483 0.80 
GyGVVFSNgERAKQLR G9 1.29 1971.02158 1.00 
TLDPNsPRDFIDSFLIRmQEEEk S6; K23 1.25 3144.50503 -1.47 
DiDvSpK I2; V4; P6 1.23 1295.63994 -1.54 
MAaSGMLLVALLVCLTVMVLMSVwQQR A3 1.19 3153.65805 1.94 
GTevYPMlgSVLR E3; V4; L8; 
G9 
1.12 2118.05962 -1.61 
HPEVeAkvHEEIDRVIGK E5; K7; V8 1.03 2607.35146 1.80 
kSdAFVPFSIgKR K1; D3; G11 0.98 1974.03496 -1.81 
kGQfkK K1; F4; K5 0.97 1099.60320 -1.42 
EsSfVekMK S2; E6; K7 0.95 1622.76592 -0.81 
SDAfvPfSIGK F4; V5; F7 0.79 1689.84050 -1.15 
GYGVVFSNGERAk K13 0.78 1557.78362 1.73 
NRQpKfEdR P4; F6 0.67 1553.76372 1.85 
hILAILQDCPSLRPPIDhLCELLPRLQAR H1; H18 0.63 3520.90317 -0.05 
MAaSGMLLVALLVCLTVMVLMSVWQQR A3 0.62 3137.65866 0.52 
MELFLFftTvMQNFr F7; T8; V10 0.56 2462.18462 0.85 
NRQPKFeDr E7; R9 0.52 1537.76712 0.78 
GYGVVFSNgeRAKQlr G9; E10; L15; 
R16 
0.50 2477.26518 1.03 
GfGVGkR K6 0.50 910.48798 -1.57 
ySLdVws W6; S7 0.50 1249.55286 0.34 
hvGfATIPr H1; V2 0.48 1219.62038 -1.23 
AvKEALLDYK V2 0.47 1323.73258 1.37 
DkEFLSLLR K2 0.46 1294.71377 -1.30 
Table 4-2. Suggested 174 Da adduct sites from analysis of tryptic peptides from 
P450 2A6 incubated with -nicotyrine. 
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4.3.3 Inactivation of P450 2A6 by 
3
H-β-nicotyrine 
 Samples of 
3
H-β-nicotyrine incubated with P450 2A6 in the presence or absence 
of NADPH were separated by HPLC and analyzed by Radioflow and UV.  Retention 
time (21 min) of P450 2A6 was determined prior to the analyses (Figure 4-5).  Analysis 
showed no radioactivity eluted with the P450 2A6 protein compared to a control (no 
NADPH).  There was more background radioactivity seen throughout the +NADPH 
sample, however it accounted for less than 10% of the total radioactivity in the sample.   
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Figure 4-5.  LC/Radioflow/UV analysis of P450 2A6 metabolism of with 
3
H-β-nicotyrine in the 
presence (A and B) or absence (C and D) of NADPH.  Radioflow traces are shown on the top (A 
and C) and UV traces on the bottom (B and D). 
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4.3.4 GSH effect on menthofuran and β-nicotyrine-mediated inactivation of P450 2A6 
To trap reactive intermediates and potentially protect P450 2A6 from inactivation 
glutathione or semicarbazide were included in the reaction mixture. Menthofuran and β-
nicotyrine concentrations were chosen so that an equal loss of enzyme activity occurred 
for each compound, about 60% (Table 4-3). Neither trapping agent protected P450 2A6 
from inactivation by menthofuran or β-nicotyrine. However, under the conditions of these 
experiments (10 min) the extent of β-nicotyrine-mediated inactivation in the presence of 
glutathione or semicarbazide was greater than in the absence of these agents (Table 4-3). 
After 30 min, the extent of β-nicotyrine mediated P450 2A6 inactivation in the samples 
with and without glutathione were similar. Therefore, glutathione and semicarbazide 
appear to accelerate the rate of inactivation by β-nicotyrine.  It should be mentioned that, 
attempts to identify a glutathione adduct were carried out with no positive results (data 
not shown).   
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Table 4-3. Effect of NADPH and trapping agents on the inhibition of P450 2A6 activity 
by menthofuran and β-nicotyrine 
 
Components
Activityb Amount 
Remainingc0 min 10 min
% %
Menthofuran (5M) 100 100 100
NADPH 91 11 81 3 90
Menthofuran (5M) +NADPH 107 9 46 14 43
+Glutathione 115 13 56 3 48
+ Semicarbazide 104 3 42 3 40
-nicotyrine (20M) 100 100 100
NADPH 90 12 83 3 86
-nicotyrine (20M) +NADPH 89 19 32 2 35
+Glutathione 96 25 13 7 14
+ Semicarbazide 83 14 10 1 13
a Samples were prepared as described in the Materials and methods.  Reconstituted 
enzyme was incubated for 10 minutes at 30 °C in the presence of 5 µM Menthofuran or 
20 µM -nicotyrine and 10 µM Glutathione or 10 µM Semicarbazide.
b Values are means  S.D. from three experiments.  Percent activity remaining is 
compared to control samples that contained no NADPH.
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4.4 Discussion 
 The experiments presented in this chapter were designed to identify the mass of 
the menthofuran and β-nicotyrine-generated adduct and the site of apoprotein 
modification.  Unfortunately, the results are largely negative or inconclusive.  They are 
useful in some regard, and are therefore this chapter is included. 
 Because previous research using immunochemical methods demonstrated 
covalent binding of menthofuran metabolites to the P450 2A6 protein, menthofuran was 
used as a positive control 
105
.  Therefore, it was expected that a mass shift would be 
apparent in menthofuran-treated P450 2A6.  Using a high mass-accuracy instrument, a 
mass shift of 150 Da was seen (Figure 4-3, C), which corresponds to the mass of the 
theoretical menthofuran adduct, if the menthofuran epoxide were added (Figure 4-2, A).  
LC-MS/MS analysis of peptides generated from menthofuran-inactivated P450 2A6 that 
looked for an addition of 150 Da mass shift were inconclusive.  LC-MS analysis of 
menthofuran-inactivatd whole P450 2A6 showed a mass shift of 17 Da as the most 
abundant peak in the deconvoluted spectrum.  The addition of 17 Da could be an oxygen, 
as the mass accuracy of the instrument is greater than ± 1 Da. Although the chemistry 
behind this result is not yet understood, it is clear that the 17 Da mass shift was dependent 
on NADPH and menthofuran, and is likely a byproduct of catalytic turnover of the 
enzyme.  By comparing P450 2A6 peak in the total ion chromatograms from 
menthofuran-modified and control experiments, it is seen that treatment results in a 
smaller P450 2A6 peak (Figure 4-3). This could occur because menthofuran-modified 
enzyme is less soluble or because it does not ionize as well in the MS.  Regardless, the 
quality of the results are diminished. 
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8-Methoxypsoralen (8-MOP) was also used as a positive control based on 
research in which LC-MS analysis of the adducted protein indicated an increase in the 
mass of 232 Da compared with the unadducted protein 
71
.  Under conditions that 
mimicked those from that paper, only one of three replicates resulted in a mass-shift of 
232 Da.  The other two mass-shifts (121 and 337 Da) are unlikely 8-MOP adducts and 
were considered false-positives.  The lack of consistent results in replicates raises 
questions to the legitimacy of this result.   
In parallel, β-nicotyrine-treated P450 2A6 was analyzed.  Similar to the results 
with 8-MOP-treated samples, three different mass-shifts were observed.  Each mass shift 
was observed one time of three replicates and none of these mass shifts would have 
resulted from the addition of any known β-nicotyrine metabolites and suggesting that 
these results are also false positives.  One reason for the underwhelming results could be 
that the quality of the LC-MS data from these experiments was poor.  This can be seen by 
the decreased P450 2A6 peak size in the TIC (Figure 4-4) and the background in the 
protein envelope (Figure 4-4, left inset).  Although none of the mass-shifts could be 
replicated, the results do not exclude the possibility of an adduct on the apoprotein as the 
cause of inactivation.  
Two of the masses, 102 and 106, were considered when querying data from LC-
MS/MS analysis of peptides from β-nicotyrine-inactivated P450 2A6.  If these masses are 
generated from a β-nicotyrine adduct, it would likely be a as a result of a fragment of 
thfragmentation of adduct during the ionization in the source of the mass spectrometer.  
Figure 4-2 shows how fragmentation across two bonds could explain the observed 
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masses, leaving a mass of 103 Da.  The remaining two masses used while quering data 
from LC-MS/MS analysis of peptides from β-nicotyrine-inactivated P450 2A6 
corresponded to the proposed β-nicotyrine pyrrolinone and the hydroxy-pyrrolinone 
adducts.  These experiments were inconclusive.  None of the suggested adducts were 
detected exclusively in β-nicotyrine-treated samples.  A heme adduct is a possibility, 
however, experiments in Chapter 2 of this thesis that looked at heme after β-nicotyrine-
mediated P450 2A6 inactivation showed no evidence of an adduct on the heme. 
One final piece of evidence suggests that no covalent adduct is formed during β-
nicotyrine-mediated inactivation of P450 2A6.  Radiolabeled menthofuran that was 
incubated with P450 2A6 and analyzed by HPLC/Radioflow did not result in detectable 
tritium co-eluting with the enzyme.  Instead, all of the radioactivity eluted at the 
beginning of the HPLC gradient with other small molecules.  If all of the P450 was 
inactivated by one molecule of β-nicotyrine, a covalent modification would result in an 
estimated 1 million counts (dpm) and would be expected to co-elute with the P450 2A6 
protein.  This was calculated by multiplying the specific activity of the β-nicotyrine by 
the amount of P450 in the reaction (2.22x10
12
 dpm/Ci · 1Ci/mol · 100x10
-12 
mol · 90% 
inactivation = 1,980,000 dpm).  Thus, under the conditions of this experiment, we 
concluede no protein adduct was formed.   
Menthofuran has been shown to non-specifically bind to protein after incubation 
with P450 2A6, therefore a reactive metabolite gets out of the active site 
105
.  The 
possibility a reactive β-nicotyrine metabolite binding to non-specific sites on the protein 
could explain the inconsistent MS results.  However, if this were the case, radioactive β-
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nicotyrine metabolites adducted to P450 2A6 would have been detected when it was 
incubated with 
3
H- β-nicotyrine.  Additionally, the addition of GSH or semicarbazide did 
not rescue enzyme activity during inactivation experiments suggest that the reactive 
intermediate does not leave the active site.   
  Another explanation for observing inactivation without detecting a covalent 
adduct is that a very tight binding product is generated.  In this hypothetical situation, the 
compound would bind the active site so tightly that koff, the rate constant for release of 
the compound from the enzyme, would be exceedingly small.  This, in effect, would 
produce irreversible inhibition.   
 
4.5 Conclusion 
 In summary, conclusive evidence of a covalent adduct as a result of 
menthofuran or 8-MOP-mediated inactivation of P450 2A6 was not obtained.  This does 
not rule out the possibility of a covalent adduct, however confirmation would require 
further experiments.  In the case of the β-nicotyrine-mediated inactivation of P450 2A6, 
the evidence presented here supports the conclusion that no covalent adduct is generated. 
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Chapter 5  
Comprehensive Conclusion 
 
 In this thesis the inhibition, inactivation and metabolism of a handful of 
compounds by P450 2A6 and P450 2A13 were studied.  The overarching goal of these 
studies was to elucidate the mechanism by which nicotine metabolism leads to the 
inactivation of P450 2A6 and P450 2A13.  β-Nicotyrine had been suggested to be an 
inactivator of P450 2A6 and some evidence suggested that it is a product of nicotine 
metabolism in vivo 
90.  Thus, we hypothesized that β-nicotyrine could be a metabolite of 
nicotine that leads to inactivation of P450 2A6 and P450 2A13.   
For this hypothesis to be true, β-nicotyrine would have to be a P450 2A6 and 
P450 2A13-mediated nicotine metabolite and β-nicotyrine metabolism catalyzed by these 
enzymes would result in their inactivation.  In Chapter 2, mechanism based inactivation 
of P450 2A6, but not P450 2A13 occurred during incubations with β-nicotyrine.  Then, in 
Chapter 3, we show that β-nicotyrine is generated in a time and concentration-dependent 
manner during P450 2A6-mediated metabolism of nicotine. Under the same conditions, 
P450 2A13-mediated metabolism of nicotine did not generate β-nicotyrine.  Based on 
these two results, in can be concluded that β-nicotyrine could be involved in the 
inactivation of P450 2A6 but not P450 2A13.  When inactivation of P450 2A6 and P450 
2A13 during nicotine metabolism was first observed, it was assumed that the inactivation 
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of these two enzymes occurred by the same mechanism.  These results, however, suggest 
that it is possible two different mechanisms are responsible for the inactivation of P450 
2A6 and P450 2A13 during nicotine metabolism.   
The hypothesis that the inactivation resulting from P450 2A6-mediated β-
nicotyrine metabolism was due to a covalent adduct to the enzyme was not supported by 
any of the experiments presented in this thesis.  The results in Chapter 4 indicate that a 
covalent adduct to the apoprotein is not formed and Chapter 3 detected no adduct to the 
heme.  As discussed in Chapter 4, an explanation for the observed inactivation without 
covalent binding would be a very tight binding product.  Upon review of literature that 
describes amino acid side-chains that surround a molecule that is in the P450 2A6 active 
site, there are no apparent sites for adduction.  Residues surrounding the active site are 
hydrophobic in nature, with the exception of an asparagine at 297 
70
.  Chemically, the 
inactivation happening through a very tight-binding intermediate, rather than a covalent 
bond, makes much more sense. 
To further elucidate the mechanism by which β-nicotyrine metabolism leads to 
P450 2A6 inactivation, its metabolism was characterized.  Three metabolites of β-
nicotyrine are identified and described in Chapter 3.  The results are in agreement with 
previous research that identified products of β-nicotyrine metabolism by rabbit liver 
microsomes.  The kinetic parameters of initial β-nicotyrine oxidation are estimated.  The 
Km is similar to that of P450 2A6-mediated coumarin metabolism and the Vmax is five 
times higher.  Coumarin is considered a good substrate for P450 2A6, β-nicotyrine is 
better and it is readily metabolized by this enzyme. 
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P450 2A13-mediated β-nicotyrine metabolism generated the same three products 
as did P450 2A6.  Additionally, the kinetic parameters for P450 2A13 oxidation of β-
nicotyrine were nearly the same as for P450 2A6.  These results rule out distinct 
metabolites being formed or rate of metabolism being the reason that P450 2A6, but not 
P450 2A13, is inactivated during β-nicotyrine metabolism.  Remaining explanations for 
the difference between the two enzymes point toward the larger size and more permissive 
geometry of the P450 2A13 active site.  This explanation fits well with the concept of a 
very tight, but non-covalent binding inactivating species.  In the P450 2A13 active site, 
there is essentially more room for the molecule to move around and possibly escape the 
active site.  
Ultimately, the research presented in this thesis is mechanistic and many steps 
removed from having an impact on human health.  However, results presented here can 
start to shape our understanding of whether or not β-nicotyrine could modify nicotine 
metabolism in vitro.  The amount of β-nicotyrine found in the smoke from one cigarette 
is low (25-250 nmol) compared to the nicotine (5-14 µmol), and the dissociation 
constants for both of these enzymes with P450 2A6 are similar (Chapter 2) so the 
nicotine would likely outcompete β-nicotyrine for access to the active site.  However, a 
novel finding that is presented in this thesis is that P450 2A6-mediated nicotine 
metabolism generates β-nicotyrine.  β-nicotyrine, then, is already in the active site.  Since 
we have shown that β-nicotyrine is readily metabolized by P450 2A6, it would likely be 
further metabolized to the species that inactivates the enzyme.   
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In Chapter 3, we measured the amount of β-nicotyrine generated during P450 
2A6-mediated nicotine metabolism.  This amount, however, is likely not representative of 
the true amount of β-nicotyrine nor is it useful to calculate rate constants because it is 
likely that as β-nicotyrine is generated, it is metabolized.  To accurately assess activation 
potency, an experiment quantifying all β-nicotyrine metabolites as well as inactivated 
protein should be carried out to calculate the appropriate kinetic parameters (Figure 5-1).  
This type of experiment has limitations.  To determine kinetic parameters for each step, 
metabolites must be quantified at very short times while concurrently measuring enzyme 
inactivation.  To add to the complexity, it would also be necessary to distinguish between 
sequential metabolism and metabolism that might occur after a metabolite dissociates and 
then reenters the active site of the enzyme.    
 
 
 
 
Figure 5-1.  Nicotine metabolism to -nicotyrine and P450 2A6 inactivation.   
 
Regardless of experimental difficulty, β-nicotyrine is a good candidate for further 
research with the long term goal of using it for smoking cessation.  We have shown that it 
does inactivate P450 2A6, and previous studies in which smokers are administered 8-
MOP have shown reduced smoking in a laboratory setting
88
.  As discussed in the 
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introduction to Chapter 4, mechanism-based inactivators make particularly potent drugs 
which allow for decreased dosing and subsequently less likelihood for harmful side 
effects 
125
.   Enzyme-adduct covalent complexes, however, have been shown to cause 
immune reactions leading to idiosyncratic adverse drug reactions.  Because we have 
shown evidence of a very tight-binding, but not covalent, inactive complex, this makes 
this compound that much more favorable for development toward a drug. 
A necessary next step would be to determine with human liver microsomes if β-
nicotyrine is a substrate for other P450 enzymes, if it inactivates any of those P450s and 
if it is metabolized by any other families of enzyme involved in xenobiotic metabolism.   
Additionally, published work suggests that β-nicotyrine does not have the addictive 
properties that nicotine does, and would therefore not contribute to dependence, however 
further research in this area would be needed.  
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